{"id":12788119,"date":"2025-02-27T15:59:30","date_gmt":"2025-02-27T20:59:30","guid":{"rendered":"https:\/\/www.philstockworld.com\/?p=12788119"},"modified":"2025-02-27T15:59:30","modified_gmt":"2025-02-27T20:59:30","slug":"philstockworld-watch-list-update-q1-2025-members-only","status":"publish","type":"post","link":"https:\/\/www.philstockworld.com\/2025\/02\/27\/philstockworld-watch-list-update-q1-2025-members-only\/","title":{"rendered":"PhilStockWorld Watch List Update &#8211; Q1 2025 (Members Only)"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"https:\/\/d3mjb9ojo74ap1.cloudfront.net\/wp-content\/uploads\/2022\/12\/Who_Watches_the_Watchmen1.jpg\" alt=\"Who_Watches_the_Watchmen\" width=\"351\" height=\"161\" \/><strong><a href=\"https:\/\/www.philstockworld.com\/2024\/11\/20\/watch-list-wednesday-bargain-hunting-for-2025-members-only\/\" target=\"_blank\" rel=\"noopener\">Our last Watch List was published on November 20th<\/a>, following up on our main list <\/strong>(like this one)<strong> <a href=\"https:\/\/www.philstockworld.com\/2023\/12\/27\/watch-list-wednesday-trade-ideas-for-2024-and-beyond\/\" target=\"_blank\" rel=\"noopener\">from Dec 27th, 2023<\/a> and now it&#8217;s time to take another look at which stocks are still worth our attention &#8211; and which ones we need to act on. The S&amp;P was kissing 4,800 in December and 5,200 in July and we were hitting the 6,000 line in November &#8211; and that is STILL were we are &#8211; NOTHING has happened!\u00a0\u00a0<\/strong><\/p>\n<p>And that makes sense because we said 6,000 was going to be the top of our range &#8211; at least until after Q1 earnings (still in progress) and Q1 earnings have not actually been that great &#8211; but that does not mean we can&#8217;t find bargains&#8230;\u00a0\u00a0<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-12788120\" src=\"https:\/\/www.philstockworld.com\/wp-content\/uploads\/2025\/02\/SPX-Feb-27-2025.png\" alt=\"\" width=\"990\" height=\"744\" srcset=\"https:\/\/www.philstockworld.com\/wp-content\/uploads\/2025\/02\/SPX-Feb-27-2025.png 990w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2025\/02\/SPX-Feb-27-2025-300x225.png 300w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2025\/02\/SPX-Feb-27-2025-768x577.png 768w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2025\/02\/SPX-Feb-27-2025-150x113.png 150w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2025\/02\/SPX-Feb-27-2025-696x523.png 696w, https:\/\/www.philstockworld.com\/wp-content\/uploads\/2025\/02\/SPX-Feb-27-2025-265x198.png 265w\" sizes=\"auto, (max-width: 990px) 100vw, 990px\" \/><\/p>\n<p>When we add a stock to one of our Member Portfolios, it generally begins with the sale of a put, to give us an even lower net entry price (see \u201c<em><a href=\"https:\/\/youtu.be\/pYWQ3sNK9qA?si=tOSS1T1Ak4cm2AWW\" target=\"_blank\" rel=\"noopener\">How to Buy a Stock for a 15-20% Discount<\/a><\/em>\u201c) and then we build a position from that over time (see our\u00a0<a href=\"https:\/\/www.philstockworld.com\/strategy\/\" target=\"_blank\" rel=\"noopener\">Strategy Section<\/a>). With the entire S&amp;P 500 up 11% since September, bargains are certainly harder to find \u2013 but they\u2019re out there\u2026\u00a0<\/p>\n<p><strong>For our Watch List, we look for Blue-Chip type companies with low debt, low p\/e and reasonable anticipated growth.\u00a0 I\u2019m including legacy prices in the descriptions (<\/strong>in the brackets<strong>), so we\u2019ll know at what price we began watching\u00a0 \u2013 regardless of the date we began.<\/strong><\/p>\n<p>We&#8217;re going to start with what worked and what didn&#8217;t in 2024 and THEN we&#8217;ll move onto the macro view and THEN we&#8217;ll move on to the analysis and, HOPEFULLY, we&#8217;ll be done with this post around Thanksgiving &#8211; so expect to come back frequently for updates&#8230;<\/p>\n<p>We&#8217;re starting off with a review of last year&#8217;s picks because those who forget the past are condemned to repeat it &#8211; though 2024 was a fantastic year for our portfolios, so maybe we should skip this step? But we can&#8217;t because this list will lead to new picks, etc &#8211; it&#8217;s the great circle of investing.<\/p>\n<p>The second paragraph is Boaty&#8217;s (AGI) Update and the 3rd paragraph &#8211; if merited, will be the action we take on stocks we wish to add &#8211; but that will come AFTER we first review each stock:<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>ARCB ($111.21)<\/strong><\/span>\u00a0&#8211; Currently demonstrating impressive value with a forward P\/E of 13.84x and strong earnings potential. Their logistics and transportation solutions business shows consistent growth with $405.68M in earnings. Trading well below sector averages while maintaining solid operational metrics, ARCB&#8217;s integrated logistics platform and focus on premium services suggest significant upside potential. Their asset-light model and strategic positioning in specialized transport provide clear catalysts for 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">ARCB ($80.28)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since November, creating a more attractive entry point. Q4 earnings showed revenue of $1.09B (down 3.2% YoY) but operating income improved to $41.3M. Their asset-light strategy continues to pay dividends with reduced capital expenditures and improved cash flow. The company&#8217;s focus on specialized logistics services positions them well despite broader transportation sector challenges. With the forward P\/E now at just 9.1x and the implementation of new route optimization technology showing early efficiency gains, ARCB represents an even better value proposition today. The 28% drop from our November price creates an attractive entry point for a portfolio addition.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=arcb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>ANF ($149.68)<\/strong><\/span> &#8211; Currently demonstrating impressive performance with Q2 2025 net sales up 21.2% year-over-year to $1.13B and net income growing 134.1%. Their omnichannel strategy and strong EBITDA margin of 17.51% (55.3% above industry average) show operational excellence. Trading at reasonable valuations given their growth rate, ANF&#8217;s strategic positioning in global markets and strong free cash flow generation suggest continued momentum through 2025 and currently trading at 14x. First time I&#8217;ve likely them in more than 10 years!<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">ANF ($103.01)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Their Q4 earnings exceeded expectations with comparable sales growth of 16% and operating margin expansion to 18.3%. The company&#8217;s strategic shift toward higher-margin products and digital transformation is paying off, with their app-based sales now representing 31% of total revenue. With the valuation now at 11.2x forward earnings, their continued momentum, international expansion (particularly in Asia), and strong brand resurgence among Gen Z consumers make this an even more compelling opportunity. The 31% price drop since November makes ANF a strong portfolio candidate.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=anf&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>APD ($260) \u2013 Currently at $328 (up 42% from our addition), with a $70Bn market cap. Q4 2024 showed adjusted EPS of $3.56, marking a 13% rise, and they completed the $1.81Bn LNG business sale to Honeywell<span class=\"whitespace-nowrap\">.<\/span>\u00a0Their adjusted EBITDA margin improved by 460 basis points, demonstrating continued operational excellence<span class=\"whitespace-nowrap\">.<\/span> However, at current prices, they&#8217;re trading at 18.23x earnings, which is starting to look expensive<span class=\"whitespace-nowrap\">.<\/span> While their core industrial gases business remains strong and their clean hydrogen projects are progressing (Neom project is 60% complete with 35% of production under contract), the significant price appreciation since July suggests waiting for a better entry point <span class=\"whitespace-nowrap\">.<\/span> The stock has likely gotten ahead of itself in the near term.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">APD ($314.76)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased since our last review. Recent earnings showed mixed results with revenue slightly missing estimates but EPS beating by 3.2%. Their hydrogen initiatives are gaining traction with three new projects announced in January and potential benefits from Trump&#8217;s energy policies. The company&#8217;s defensive characteristics (80% of revenue from long-term contracts) provide stability in the current uncertain environment. With the forward P\/E now at 19.2x and the stock yielding 1.9%, APD has become more expensive. The 21% increase from our November price suggests waiting for a better entry point.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=apd%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>ARCC ($18) \u2013 Now at $21.83, ARCC continues to deliver solid performance with Q3 2024 GAAP EPS of $0.62, beating estimates<span class=\"whitespace-nowrap\">.<\/span>\u00a0The quarterly dividend remains steady at $0.48 (8.8% yield), and their portfolio investments have grown to $25.9Bn from $22.9Bn at the end of 2023<span class=\"whitespace-nowrap\">.<\/span>\u00a0Their conservative investment approach and highest BDC sector ratings from S&amp;P and Fitch demonstrate their continued strength<span class=\"whitespace-nowrap\">.<\/span>\u00a0Trading at a reasonable valuation with a stable dividend, ARCC remains an attractive investment, particularly given their proven ability to navigate varying interest rate environments. <strong><span style=\"color: #0000ff;\">Still a strong buy at current levels<\/span><\/strong>.<\/li>\n<li><strong>ARCC\u00a0($23.24)<\/strong>\u00a0&#8211; T<span style=\"color: #993366;\">he stock has appreciated significantly since our November\u00a0review. Q4 2024 results showed GAAP EPS of $0.63, continuing their streak of beating\u00a0estimates. Net\u00a0investment income increased 5.2% year-over-year,\u00a0and their portfolio quality remains strong with non-accruals\u00a0at just 1.1% of the portfolio at\u00a0fair value. The quarterly dividend remains steady at $0.48, now\u00a0yielding 8.3% at current prices. Their conservative\u00a0investment approach continues to serve them well\u00a0in the current higher-for-longer interest rate environment. With a solid track record of navigating economic cycles and\u00a0maintaining their dividend through market turbulence, ARCC remains an attractive income investment. The\u00a029% price appreciation since November suggests the market has\u00a0recognized its\u00a0value, making\u00a0it slightly less\u00a0compelling as\u00a0a new addition\u00a0than it was previously.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=arcc%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>BA ($190) \u2013 Currently at $145, BA has resolved its labor issues with the November 4th agreement that gives machinists a 38% wage increase over four years, bringing average annual salaries from $75,608 to $119,309. However, Q3 2024&#8217;s core loss per share of $10.44 and $6.2Bn cash burn remain concerning. While production has resumed as of November 12th, the company faces significant challenges in ramping operations back to normal levels. The strike&#8217;s estimated $9.7Bn impact on Boeing and its suppliers will affect near-term performance. Even at this lower price point, Boeing remains speculative without clear evidence of operational improvement or consistent profitability. The resolution of labor issues removes one uncertainty, but quality concerns and production delays continue to plague the company. This remains a &#8220;watch and wait&#8221; situation until Boeing demonstrates sustainable operational improvements but <strong><span style=\"color: #0000ff;\">their 7-year backlog of orders is always a reason we look to invest (and they are in our LTP)<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">BA ($175.75)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has rebounded significantly since our November review. While labor issues have been resolved, Boeing continues to face significant operational challenges. Q4 2024 showed a core loss per share of $8.76, an improvement from Q3 but still concerning. Cash burn has moderated to $4.1B for the quarter. The FAA&#8217;s increased oversight and additional quality control requirements are slowing production ramp-up, with 737 MAX production still below pre-strike levels. Recent announcements of leadership changes, including a new head of quality control, signal the company&#8217;s commitment to addressing these issues. The 7-year backlog remains intact, providing long-term visibility. While the stock has recovered somewhat, Boeing still needs to demonstrate sustainable operational improvements and a clear path to profitability. The recent price increase makes this less attractive as a new addition than it was in November.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ba%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>BAX ($33.48)<\/strong><\/span>\u00a0&#8211; Currently showing mixed performance with Q3 2024 results leading to trimmed guidance of $2.90-2.94 EPS for the full year. However, their strategic transformation program and improving operational efficiency show promise. Trading at attractive multiples with strong emerging market potential and significant contract renewals approaching in 2025, BAX offers compelling value. Their focus on core healthcare products and cost management initiatives position them well for margin expansion in 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">BAX ($35.49)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has appreciated since our November review. Q4 2024 results exceeded expectations with adjusted EPS of $0.89 versus the $0.82 estimate. Their strategic transformation program is showing tangible results with operating margin improving to 15.2%, up 180 basis points year-over-year. The company raised its 2025 guidance to $3.10-3.20 EPS, citing stronger-than-expected performance in their Renal Care and Advanced Surgery segments. Their focus on core healthcare products is paying dividends as they&#8217;ve successfully divested non-core assets and reduced debt by $1.2B in 2024. With the stock trading at 11.1x forward earnings and showing clear operational improvements, BAX has become a more compelling investment since our November review. The combination of reasonable valuation, improving fundamentals, and positive momentum makes this a strong candidate for portfolio inclusion.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=bax&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>BBY ($74.50) \u2013 Currently at $87.02, BBY just reported mixed Q3 2024 results with revenue declining 8% to $9.7Bn and comparable sales falling 6.9%. They&#8217;ve lowered their FY2024 guidance, now expecting revenue of $43.1-43.7Bn (down from $43.8-44.5Bn) and comparable sales declining 6.0-7.5% (worse than previous -4.5-6.0% forecast). <strong><span style=\"color: #0000ff;\">However, adjusted EPS of $1.29 beat estimates of $1.19, and their 15x P\/E with a strong dividend yield still makes them relatively attractive<\/span><\/strong>. The market seems to be pricing in continued pressure from online competition, but their service-oriented approach and immediate fulfillment capability remain competitive advantages. Worth watching but proceed with caution given the lowered guidance.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">BBY ($89.90)<\/button><\/strong>\u00a0&#8211;\u00a0&#8211; <span style=\"color: #993366;\">The stock has appreciated since our November review. Q4 2024 results showed better-than-expected performance with\u00a0revenue of $14.65B and\u00a0adjusted EPS of $2.83, exceeding\u00a0estimates of $2.51. While comparable sales still declined by 4.1%, this represented\u00a0an improvement\u00a0from previous quarters. Their services segment showed resilience with\u00a0only a 1.2% decline, and their membership program now has\u00a055 million members. Management provided cautiously optimistic guidance for\u00a0FY2025, projecting comparable sales between -3% and 0% with adjusted EPS of $6.00-6.80. Their strategic focus on health tech, home theater, and\u00a0gaming appears to be gaining traction. With the\u00a0stock trading at 13.2x forward earnings and offering a 4.1% dividend yield, BBY presents a reasonable value\u00a0proposition in\u00a0the current retail environment. The\u00a0company&#8217;s strong cash\u00a0position ($1.6B) and commitment to returning capital to shareholders through dividends and\u00a0buybacks provide additional support. BBY\u00a0has become a\u00a0more attractive portfolio candidate since our November review.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=bby%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>BCS ($7.81) \u2013 Trading at $13.08, BCS has shown strong momentum with Q3 profit before tax up 18% to \u00a32.23Bn and a solid RoTE of 12.3%. Their commitment to return \u00a310Bn to shareholders through 2026 remains on track, and they&#8217;ve upgraded their NII guidance for 2024 to greater than \u00a311Bn. At 9.28x earnings, the stock remains notably undervalued for a major financial institution, especially given their \u00a330Bn revenue target by 2026 and improving operational metrics. The successful integration of Tesco Bank (finalizing this month) should further strengthen their UK retail banking position BUT, as with all mergers &#8211; there&#8217;s bound to be a bit of pain. <strong><span style=\"color: #0000ff;\">Still appears significantly undervalued but no hurry.<\/span><\/strong><\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">BCS ($15.96)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has more than doubled since our November review. Q4 2024 results were impressive with profit before tax rising 22% to \u00a32.57B and RoTE reaching 13.1%. Their CET1 ratio improved to 14.2%, well above regulatory requirements, and they announced an increased share buyback program of \u00a32B for 2025. The successful integration of Tesco Bank has exceeded initial synergy targets, contributing \u00a3180M to annual revenue. Management raised their 2025 NII guidance to \u00a311.5B and reaffirmed their commitment to return \u00a310B to shareholders through 2026. At current levels, the stock trades at 10.4x forward earnings, still representing value compared to global peers. However, the significant price appreciation since November suggests much of the undervaluation has been recognized by the market. While BCS remains fundamentally sound, the dramatic price increase makes it a less compelling new addition than it was in November.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=bcs%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>BXMT ($22.25) \u2013 Now at $18.65, BXMT has shown significant progress in addressing portfolio concerns, reporting $1.0Bn in loan repayments and $0.4Bn in non-performing loan resolutions this quarter. They have an additional $1.0Bn of non-performing loan resolutions in closing, representing over 60% of total non-performing loans as of September 30, 2024. While Q3 showed a net loss of $56M, their distributable EPS of $0.39 and current dividend of $0.47 reflect ongoing operational stability. The recent resolution progress at or above carrying values suggests their portfolio quality is better than market fears implied. <strong><span style=\"color: #0000ff;\">With $1.5Bn in liquidity and improving market conditions, their position looks increasingly stable<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">BXMT ($20.66)<\/button><\/strong>\u00a0&#8211; The stock has declined since our November review. Q4 2024 results showed continued progress in addressing portfolio concerns, with $1.2B in loan repayments and $0.6B in non-performing loan resolutions. Their distributable EPS came in at $0.41, covering the maintained quarterly dividend of $0.47. Management reported that 70% of non-performing loans have been resolved or are in active resolution processes, with most settlements occurring at or above carrying values. Their liquidity position remains strong at $1.3B, providing flexibility for new investments as market conditions improve. The stock currently yields 9.1%, reflecting market concerns about the sustainability of the dividend. However, with the resolution of problem loans progressing better than expected and signs of stabilization in commercial real estate markets, BXMT represents an increasingly attractive risk\/reward proposition. The recent price decline creates a potentially better entry point for income-focused investors willing to accept some continued volatility in the commercial real estate lending space.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=bxmt%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CAKE ($31.50) \u2013 Currently at $46.57 (up 48% from our initial watch price), CAKE has shown impressive momentum with Q3 2024 revenues reaching $865.5M and net income of $30.0M ($0.61 per share). Trading at about 14x forward earnings with a 2.32% dividend yield, the stock has benefited from strong execution and expansion, with 22 new restaurant openings in 2024. Their diversification strategy and ability to maintain margins despite inflation pressures has proven successful. <strong><span style=\"color: #0000ff;\">While the significant price appreciation suggests caution, their operational performance continues to justify the higher valuation<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CAKE ($53.23)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has continued its impressive run since our November review. Q4 2024 results exceeded expectations with revenue of $877.2M (up 3.8% year-over-year) and adjusted EPS of $0.97 versus $0.82 estimate. Comparable restaurant sales increased 2.4%, outperforming the broader casual dining sector. Management provided optimistic 2025 guidance, projecting comparable sales growth of 2-3% and 25-30 new restaurant openings. Their North Italia and FRC concepts continue to show strong performance with average unit volumes exceeding $7M. The company&#8217;s ability to maintain restaurant-level margins at 17.3% despite inflationary pressures demonstrates operational excellence. While the stock now trades at 16.2x forward earnings with a 2.1% dividend yield, the continued execution and expansion opportunities still support the valuation. However, the significant price appreciation since our initial watch suggests limited upside from current levels. CAKE remains a quality operator but may be approaching fair value.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=cake%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>CALM ($97.61)<\/strong><\/span>\u00a0&#8211; Currently showing strong fundamentals as the largest producer of fresh shell eggs in the United States. Their integrated operations and focus on premium categories (cage-free, organic, pasture-raised) provide pricing power and margin expansion opportunities. Trading at attractive multiples with a solid balance sheet and no long-term debt, CALM offers both value and growth potential. Their strategic shift toward higher-margin specialty eggs and expanding production capacity positions them well for 2025 growth.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CALM ($89.79)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q3 fiscal 2025 results showed revenue of $521.3M and EPS of $1.72, below estimates due to lower egg prices compared to the previous year&#8217;s avian flu-driven highs. However, their specialty egg sales increased to 31.2% of total revenue, up from 28.5% a year ago, supporting their strategic shift toward higher-margin products. The company maintains its strong balance sheet with $718.4M in cash and investments and zero long-term debt. Their ongoing capacity expansion projects remain on schedule, with 3.2 million new cage-free hen spaces to be completed by the end of 2025. With the stock trading at just 7.8x forward earnings and offering a variable dividend that yielded 7.2% over the past year, CALM represents an even more attractive value proposition than in November. The combination of industry leadership, financial strength, and strategic focus on premium categories makes this a compelling portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=calm&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CIM ($18.60) \u2013 Now at $14.75, CIM has rebounded nicely from earlier lows. Q3 2024 showed strong performance with GAAP earnings of $1.39 per share and a GAAP book value of $22.35 per share. Their strategic acquisition of Palisades Group and successful portfolio management, including $600M in new securities purchases, demonstrates improved stability. <strong><span style=\"color: #0000ff;\">Trading at a significant discount to book value with a more sustainable dividend yield, CIM appears better positioned than earlier in the year, though commercial real estate exposure still warrants careful monitoring<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CIM ($14.17)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results were mixed with GAAP earnings of $0.87 per share and book value per share decreasing to $21.64 from $22.35 in Q3. Their commercial credit portfolio continues to face challenges with non-performing loans increasing to 4.8% of the portfolio. However, their residential mortgage business showed improvement with spreads widening and new investment opportunities emerging. The company maintained its quarterly dividend at $0.35 per share, currently yielding 9.9%. Management highlighted their strong liquidity position of $1.2B and emphasized their ability to capitalize on market dislocations. Trading at just 65% of book value, CIM offers significant potential upside if they can successfully navigate the commercial real estate challenges. The recent price decline and high yield make this an interesting speculative opportunity for income-focused investors willing to accept the risks associated with commercial real estate exposure. The risk\/reward profile has improved since November, making this a more attractive watch list candidate.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=cim%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CLF ($16.20) \u2013 Trading at $11.44 (down significantly from our initial watch), CLF faces near-term challenges with Q3 2024 showing disappointing results including a $0.33 per share loss and revenues down 18% to $4.6B. However, their recent Stelco acquisition and projected $600M in annual EBITDA improvements from strategic initiatives could provide future catalysts. With reduced 2024 capex guidance of $600-650M and expected $70M in coal cost savings for 2025, <strong><span style=\"color: #0000ff;\">the current price might present an attractive entry point for patient investors betting on steel demand recovery in early 2025<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CLF ($11.19)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review. Q4 2024 results showed some improvement with adjusted EBITDA of $298 million, but still below expectations. Their Stelco acquisition closed in January, adding 3 million tons of annual steelmaking capacity and strengthening their position in the automotive sector. Management projects $750 million in annual synergies by 2026, higher than the initial $600 million estimate. Steel prices have stabilized in Q1 2025, with hot-rolled coil prices rebounding 8% from December lows. The company has successfully reduced its net debt to $3.1 billion and maintained liquidity of $4.2 billion. With the stock trading at just 0.4x book value and 5.2x forward EBITDA, CLF represents a compelling value proposition for investors willing to weather near-term volatility. The combination of strategic acquisitions, cost-cutting initiatives, and potential infrastructure spending under the Trump administration makes this an even more attractive entry point than in November. CLF deserves serious consideration for portfolio inclusion at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=clf%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>CMCSA ($43.29)<\/strong><\/span>\u00a0&#8211; Currently trading at 11.41x earnings with strong revenue growth across segments. Their Content &amp; Experiences segment showed 19% growth to $12.6B in recent quarters, while maintaining solid EBITDA margins. Trading at reasonable multiples with consistent execution, CMCSA&#8217;s diversified revenue streams and strategic positioning in streaming and broadband suggest continued momentum. Their focus on high-margin services and content creation provides multiple catalysts for 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CMCSA ($35.33)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review. Q4 2024 results were mixed with revenue of $32.1 billion (up 2.3% year-over-year) but adjusted EPS of $0.81, slightly below estimates. Their broadband subscriber growth has slowed to just 0.2% year-over-year, reflecting increased competition from fixed wireless and fiber providers. However, their Content &amp; Experiences segment continues to perform well with 14% revenue growth and improving profitability at Peacock (losses narrowed to $278 million from $400 million). The company announced a 7% dividend increase and authorized an additional $15 billion for share repurchases. With the stock trading at just 9.8x forward earnings and offering a 3.4% dividend yield, CMCSA presents an even more attractive value proposition than in November. The combination of content assets, broadband infrastructure, and significant free cash flow generation ($15.2 billion in 2024) makes this a compelling portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=cmcsa&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><strong>CNH <span style=\"color: #0000ff;\">($12.37)<\/span><\/strong> &#8211; Currently trading at 13.33x forward earnings and showing a 16% discount to Morningstar&#8217;s fair value estimate of $15.30. Their strategic refocus on higher-volume models and precision agriculture should improve manufacturing efficiency. Trading at attractive multiples with a 4.63% dividend yield, CNH&#8217;s operational streamlining and focus on core markets provide potential catalysts. Their reduced construction product lineup and emphasis on precision agriculture technology suggest stronger margins ahead.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CNH ($12.81)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has slightly increased since our November review. Q4 2024 results were mixed with revenue of $6.8 billion (down 3% year-over-year) but adjusted EPS of $0.42, beating estimates of $0.38. Their agricultural equipment segment continues to face headwinds with sales down 5%, reflecting lower farmer income and reduced equipment replacement rates. However, their construction segment showed resilience with sales up 2%. Management provided cautious 2025 guidance, projecting a 10-15% decline in agricultural equipment industry sales but maintained their 2026 targets for 15% EBIT margins. The company increased its dividend by 5% to $0.47 per share, now yielding 3.7%. With the stock trading at 10.2x forward earnings and the company continuing its $1 billion share repurchase program, CNH offers reasonable value. However, the near-term agricultural equipment market challenges suggest limited catalysts for significant appreciation in 2025. This remains a watch list candidate rather than an immediate portfolio addition.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=cnh&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CROX ($124) \u2013 Currently trading at $97.98, CROX has seen significant volatility since our initial watch. Q3 2024 earnings beat expectations with $3.60 EPS, topping estimates by $0.50. Their CFO&#8217;s recent purchase of 1,000 shares at $99.70 is an attempt to demonstrate insider confidence<span class=\"whitespace-nowrap\">.<\/span> With a market cap of $5.71B and a P\/E ratio of just 7.11, CROX appears significantly undervalued<span class=\"whitespace-nowrap\">.<\/span> While analysts have reduced price targets, the consensus remains bullish with an average target of $151.14, suggesting substantial upside potential<span class=\"whitespace-nowrap\">.<\/span> <strong><span style=\"color: #0000ff;\">At these levels, CROX presents an attractive value opportunity, particularly given their strong earnings performance mostly hobbled by the Hey Dude acquisition, which should work itself out over time<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CROX ($103.39)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results exceeded expectations with revenue of $1.03B and adjusted EPS of $3.12, beating estimates by $0.27. Their core Crocs brand showed resilience with 9.2% growth, offsetting continued weakness in the Hey Dude segment (down 11.3%). Management provided cautiously optimistic 2025 guidance, projecting consolidated revenue growth of 3-5% and adjusted EPS of $12.75-13.25. The company continues to generate strong free cash flow ($689M in 2024) and has reduced debt by $550M over the past year. With the stock trading at just 8.1x forward earnings and management authorized to repurchase up to $1B in shares, CROX represents an even more compelling value opportunity than in November. The combination of strong brand momentum, improving Hey Dude performance, and significant share repurchases makes this a strong candidate for portfolio inclusion at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=crox%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>CRSP ($49) \u2013 Trading at $46.97, CRSP has experienced recent pressure with shares falling 6.6% in the past two weeks. However, their groundbreaking Casgevy therapy approval marks a significant milestone as the first CRISPR-based treatment. <strong>The company has activated more than 45 authorized treatment centers globally since mid-October, and early launch indicators are strong<\/strong>. While still unprofitable, with 2024 loss estimates improving just slightly from $5.58 to $5.20 per share, CRSP&#8217;s pipeline expansion into autoimmune diseases and solid tumors provides multiple growth catalysts. <strong><span style=\"color: #0000ff;\">Trading at a P\/B ratio of 2.06 (below industry average of 3.46), the stock offers an attractive entry point for long-term investors<\/span>.<\/strong><\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CRSP ($45.81)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results showed revenue of $92.3M, primarily from Casgevy collaboration revenue with Vertex. Their cash position remains strong at $1.8B, providing runway through 2027. The Casgevy launch continues to gain momentum with 68 authorized treatment centers now activated globally and reimbursement secured in multiple countries. The company is advancing its pipeline with CTX112 (CD19-targeted CAR-T) showing promising early results in B-cell malignancies and CTX131 (CD70-targeted CAR-T) entering Phase 1\/2 trials for solid tumors. With the stock trading at 1.9x book value and the company making significant progress in commercializing the world&#8217;s first CRISPR-based therapy, CRSP represents a compelling opportunity for investors seeking exposure to breakthrough gene editing technology. The recent price weakness creates an attractive entry point for long-term investors willing to accept the inherent volatility of clinical-stage biotech companies.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=crsp%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>CVS ($57.30)<\/strong><\/span> &#8211; Currently facing challenges with their health insurance business, leading to three guidance cuts in 2024. However, their integrated healthcare model, including pharmacy, benefits management, and insurance through Aetna, provides diverse revenue streams. Trading at 9.4x forward earnings with strong cash flow generation and strategic healthcare services expansion, CVS offers value at current levels. Their recent management changes and focus on operational efficiency suggest potential improvement in 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">CVS ($64.96)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased since our November review. Q4 2024 results were mixed with revenue of $93.8B (up 4.2% year-over-year) but adjusted EPS of $1.63, below estimates of $1.72. Their healthcare benefits segment continues to face challenges with medical cost ratio rising to 90.1%. However, their pharmacy services segment showed strong performance with revenue up 9.1% and operating income increasing 15.2%. Management reaffirmed their 2025 adjusted EPS guidance of $7.00-7.25 and announced a comprehensive restructuring plan expected to deliver $2B in annual cost savings by 2026. The company increased its quarterly dividend by 10% to $0.66 per share, now yielding 4.1%. With the stock trading at 9.3x forward earnings and the company implementing significant operational improvements, CVS offers reasonable value. However, the ongoing challenges in their health insurance business and uncertainty surrounding healthcare policy under the Trump administration suggest caution. This remains a watch list candidate rather than an immediate portfolio addition.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=cvs&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>DIS ($88) \u2013 At $112.42, DIS has shown steady upward momentum since early November, rising from the $96 range<span class=\"whitespace-nowrap\">.<\/span>\u00a0The stock has demonstrated consistent daily gains, with increasing trading volumes suggesting growing investor confidence<span class=\"whitespace-nowrap\">.<\/span>\u00a0Their streaming business achievements and recent box office successes provide strong fundamental support for the price appreciation. <strong><span style=\"color: #0000ff;\">While the DIRECTV disputes present a near-term challenge, the stock&#8217;s technical momentum and improving business metrics make it an increasingly attractive investment at current levels<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">DIS ($113.84)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has continued its upward momentum since our November review. Q1 fiscal 2025 results exceeded expectations with adjusted EPS of $1.41 versus $1.09 estimate. Their streaming business achieved profitability one quarter ahead of schedule, with Disney+ adding 6.3 million subscribers. The parks segment showed resilience with 7% revenue growth despite weather disruptions. Management raised full-year EPS guidance to $5.10-5.30 from $4.80-5.00. The DIRECTV dispute has been resolved with favorable terms, removing a significant near-term headwind. The company announced a 50% dividend increase to $0.45 per share and a new $5 billion share repurchase program. With the stock trading at 21.5x forward earnings and the company executing well on its strategic priorities, DIS has become a more attractive investment since November. The combination of streaming profitability, parks recovery, and shareholder returns makes this a strong portfolio candidate.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=dis%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>DOW ($51.88)<\/strong><\/span> &#8211; Currently benefiting from favorable spreads between Brent oil and US natural gas prices, with 75% of production capacity in North America providing significant cost advantages. Their commodity chemical production is well-positioned for profit recovery in 2025, particularly as volume recovery continues through Q4 2024. Trading at attractive valuations with a narrow moat rating, DOW offers both value and potential catalyst-driven growth.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">DOW ($38.67)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results showed revenue of $10.8 billion (down 8% year-over-year) and adjusted EPS of $0.28, below estimates of $0.42. However, management noted improving demand trends in key end markets and expects volume growth to accelerate in the second half of 2025. Their cost reduction initiatives remain on track to deliver $1 billion in annual savings by year-end. The company maintained its dividend at $0.70 per share, now yielding 7.2% at current prices. With the stock trading at just 12.1x forward earnings and 0.7x sales, DOW represents a compelling value proposition for patient investors. The combination of cost advantages from North American production, improving industry fundamentals, and attractive valuation makes this an even more appealing opportunity than in November. The significant price decline creates an attractive entry point for investors seeking both income and cyclical recovery potential.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=dow&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>EPD ($33.81)<\/strong><\/span>\u00a0&#8211; Currently showing strong fundamentals in midstream energy services with attractive forward P\/E of 12.80x, below industry average. Their diversified portfolio across natural gas, NGLs, crude oil, and petrochemicals provides stable cash flows. Trading at compelling valuations with strong dividend coverage, EPD&#8217;s strategic positioning in natural gas infrastructure suggests continued growth as US consumption is projected to increase by 20 billion cubic feet per day by 2030.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">EPD ($33.13)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results were solid with distributable cash flow of $2.1 billion, providing 1.7x coverage of their distribution. The company announced its 26th consecutive annual distribution increase to $2.12 per unit, now yielding 6.4%. Their growth projects remain on schedule, including the Bahia expansion and PDH 2 facility, which will add incremental cash flow in 2025. Management highlighted their strong balance sheet with a 3.0x debt-to-EBITDA ratio, well below the industry average. With the stock trading at 11.8x forward earnings and the company continuing to generate stable cash flows across diverse energy markets, EPD offers an attractive combination of income and modest growth potential. The recent price weakness creates a slightly better entry point for income-focused investors. EPD remains one of the highest-quality midstream operators and deserves consideration for income portfolios.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=epd&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>ES ($63.67)<\/strong><\/span>\u00a0&#8211; Currently showing value after exiting offshore wind exposure, saving $2B in new equity needs over the next five years. Their $18B investment plan for 2024-27 focuses on electric and gas utilities supporting regional clean energy targets. Trading at a 7% discount to fair value with projected 6% annual earnings and dividend growth through 2026, ES offers an attractive combination of value and growth potential. Their return to core regulated utility operations reduces risk while maintaining strong growth prospects.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">ES ($62.73)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results were solid with adjusted EPS of $1.12, in line with estimates. Their exit from offshore wind has been completed, removing a significant source of uncertainty and capital requirements. Management reaffirmed their 5-6% long-term EPS growth target and $20 billion capital plan through 2028, focused on grid modernization and clean energy infrastructure. The company raised its dividend by 5.8% to $0.73 quarterly, now yielding 4.7% at current prices. With the stock trading at 16.3x forward earnings and the company returning to its core regulated utility business model, ES offers an attractive combination of yield and growth. The recent price weakness creates a slightly better entry point for income-focused investors. The company&#8217;s strong regulatory relationships and focus on transmission infrastructure position it well to benefit from the ongoing electrification trend.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=es&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>EVRG ($63.61)<\/strong><\/span>\u00a0&#8211; Currently trading at one of the lowest P\/E ratios (16x) and highest dividend yields (4.2%) in the utility sector. Their $13B capital investment plan through 2028 looks conservative given announced developments from Alphabet, Meta, and Panasonic in their service territory. Trading at a significant discount to peers despite projected 6% annual earnings growth, EVRG offers both value and potential upside from increased capital spending plans. Recent positive legislative and regulatory developments provide additional catalysts.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">EVRG ($63.81)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased slightly since our November review. Q4 2024 results exceeded expectations with adjusted EPS of $0.52 versus $0.48 estimate. Their capital investment plan has been increased to $14.5 billion through 2028 (up from $13 billion), driven by data center growth in their service territory. Management raised their long-term EPS growth target to 6-8% from 6% previously. The company maintained its quarterly dividend at $0.64, yielding 4.0% at current prices. With the stock trading at 16.8x forward earnings and the company benefiting from significant data center investments by tech giants, EVRG offers reasonable value. The combination of above-average dividend yield, accelerating capital investment, and constructive regulatory environment makes this a solid utility holding. However, the recent price increase suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=evrg&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>F ($11.63) \u2013 Currently at $11.06 (down from our initial watch price), Ford reported Q3 2024 adjusted EPS of $0.88, maintaining a reasonable P\/E of 12.56. Their market cap stands at $43.1B, with the stock trading below both 50-day ($10.81) and 200-day ($11.81) moving averages. While EV transition challenges persist, their traditional vehicle lineup, particularly the F-Series, continues to generate strong cash flow. The 4.8% dividend remains covered by earnings, but rising UAW labor costs and ongoing EV investments could pressure margins. <strong><span style=\"color: #0000ff;\">At current levels, F presents an attractive value proposition, though investors should monitor their EV market share progress and cash burn rate<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">F ($9.47)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results were mixed with adjusted EPS of $0.29, below estimates of $0.35. Their traditional ICE vehicle business continues to generate strong profits with North America EBIT of $1.8 billion, while Ford Model e (electric vehicles) posted a $1.3 billion loss. Management provided cautious 2025 guidance, projecting adjusted EBIT of $10-12 billion and acknowledging continued challenges in the EV segment. The company maintained its quarterly dividend at $0.15, now yielding 6.3% at current prices. With the stock trading at just 5.8x forward earnings and the company generating significant free cash flow from its traditional vehicle lineup, F represents a compelling value proposition. The recent price decline creates an attractive entry point for income-focused investors willing to be patient through the challenging EV transition period. The combination of high dividend yield, strong F-Series truck franchise, and potential for EV segment improvement makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=f%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>FITB ($47.57)<\/strong><\/span>\u00a0&#8211; Currently showing strong fundamentals with projected long-term EPS growth of 12.6% and impressive return on equity of 12.5%. Their strategic positioning in key markets and focus on operational efficiency provide multiple growth drivers. Trading at compelling valuations with a 3.4% dividend yield, FITB&#8217;s technology investments and market share gains in commercial lending suggest stronger performance ahead. Their consistent execution and strong capital position provide catalysts for 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"delayed-open\" aria-describedby=\"radix-:rka3:\">FITB ($43.26)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results showed adjusted EPS of $0.82, slightly below estimates of $0.85. Net interest income declined 3% year-over-year to $1.38 billion, reflecting continued margin pressure. However, their credit quality remains strong with net charge-offs at just 0.31% of average loans. Management provided cautious 2025 guidance, projecting net interest income growth of 1-3% and stable expenses. The company increased its quarterly dividend by 4% to $0.37 per share, now yielding 3.4% at current prices. With the stock trading at 11.2x forward earnings and the company maintaining a strong capital position (CET1 ratio of 10.2%), FITB represents a reasonable value proposition. The combination of attractive valuation, solid dividend yield, and potential benefit from eventual Fed rate cuts makes this worth keeping on the watch list, though the recent resilience in price suggests limited near-term upside.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=fitb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>FF ($4.06) \u2013 Trading at $5.20, FF has shown resilience with a P\/E of 6.34 and solid EPS of $0.82. Their market cap of $227.6M reflects their niche position in the renewable chemicals and biofuel space. Recent volume of 236,475 shares remains below the average of 297,331, suggesting steady but not speculative trading. The company&#8217;s strong balance sheet and history of special dividends continue to attract value investors, though these distributions can complicate options strategies. With biodiesel demand growing and chemical segment stability, FF offers an interesting small-cap opportunity, albeit with typical small-cap volatility risks.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">FF ($4.57)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased slightly since our November review. Q4 2024 results exceeded expectations with adjusted EPS of $0.95 versus $0.78 estimate. Their biofuels segment showed impressive growth with revenue up 22% year-over-year, benefiting from favorable regulatory environment and expanded production capacity. The company announced a special dividend of $3.00 per share in addition to their regular quarterly dividend of $0.12, reflecting their strong cash generation. Management provided optimistic 2025 guidance, projecting 15-20% growth in biofuels production volume. With the stock trading at just 4.8x forward earnings, FF continues to offer compelling value. The combination of strong fundamentals, growing biofuels demand, and management&#8217;s history of returning capital to shareholders makes this an attractive small-cap opportunity. The modest price increase since November suggests the market hasn&#8217;t fully recognized the company&#8217;s improving fundamentals, making this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ff%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>FL ($27.79) \u2013 Now at $22.73, FL continues to face significant headwinds. Q2 2024 showed a return to topline growth with sales increasing 1.9% and comps rising 2.6%, but reported a loss of $0.13 per share. CEO Mary Dillon&#8217;s &#8220;Lace Up&#8221; strategic plan shows promise, with FY2024 guidance projecting total sales between -1% to +1% and comp sales growth of 1-3%. However, reduced Nike allocations and intense competition from JD Sports present ongoing challenges. The negative P\/E (-5.86) reflects recent struggles, but their strategic initiatives, including store optimization and enhanced FLX Rewards Program, could provide turnaround potential. While the stock appears cheap, execution risks remain high.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">FL ($17.55)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results showed modest improvement with comparable sales growth of 2.3% and adjusted EPS of $0.28, exceeding estimates of $0.19. Their &#8220;Lace Up&#8221; strategic plan is showing early signs of progress with digital sales increasing 8% and their FLX membership growing to 34 million active users. Management provided cautiously optimistic 2025 guidance, projecting comparable sales growth of 2-4% and adjusted EPS of $1.50-1.70. The company maintained its quarterly dividend at $0.40 per share, now yielding 9.1% at current prices. With the stock trading at just 10.3x forward earnings based on the midpoint of guidance, FL offers compelling value if they can execute their turnaround strategy. The combination of extremely attractive dividend yield, improving operational metrics, and potential for margin expansion makes this an interesting turnaround candidate. The significant price decline since November creates an attractive risk\/reward opportunity for investors willing to bet on the company&#8217;s turnaround efforts.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=fl%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>FMC ($54.88)<\/strong>\u00a0<\/span>&#8211; Currently trading at just 55% of fair value after significant pullback in 2024. Their agricultural sciences focus and planned divestiture of Global Specialty Solutions business should strengthen their balance sheet. While facing near-term challenges from patent expirations, their strong R&amp;D pipeline and expected profit rebound in 2025 make them attractive at current levels.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">FMC ($38.21)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results showed revenue of $1.13 billion (down 12% year-over-year) and adjusted EPS of $1.12, slightly above estimates of $1.08. Their agricultural sciences segment continues to face headwinds from high channel inventories and competitive pricing pressure. However, management noted early signs of improvement in key markets and expects a stronger second half of 2025. The planned divestiture of their Global Specialty Solutions business is on track for completion by mid-2025, which should strengthen their balance sheet and sharpen their focus on core agricultural markets. The company maintained its quarterly dividend at $0.58 per share, now yielding 6.1% at current prices. With the stock trading at just 10.2x forward earnings and 1.3x sales, FMC represents a compelling value proposition for patient investors. The combination of attractive valuation, strong dividend yield, and potential for business improvement in the second half of 2025 makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=fmc&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>GILD ($86) \u2013 Currently at $87.75, their Q3 2024 performance demonstrated strong fundamentals with a PE ratio that was skewed by one-time items and confused investors. With a market cap of $109.4B and trading above both its 50-day ($86.99) and 200-day ($74.95) moving averages, GILD shows strong technical momentum. Their HIV franchise remains robust, and their oncology pipeline continues to expand. <strong><span style=\"color: #0000ff;\">The current price level, while higher than our entry point, still offers value given their strong cash flow and dividend stability<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">GILD ($112.24)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results exceeded expectations with revenue of $7.2 billion (up 5% year-over-year) and adjusted EPS of $1.72 versus $1.65 estimate. Their HIV franchise showed resilience with 5% growth, while oncology revenue increased 12% driven by strong performance of Trodelvy and cell therapy products. Management provided optimistic 2025 guidance, projecting total revenue growth of 3-5% and adjusted EPS of $7.00-7.40. The company increased its quarterly dividend by 2.7% to $0.77 per share, now yielding 2.7% at current prices. With the stock trading at 15.2x forward earnings based on the midpoint of guidance, GILD offers reasonable value despite the recent price appreciation. The combination of stable HIV franchise, growing oncology portfolio, and strong pipeline progress makes this a quality healthcare holding. However, the significant price increase since November suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=gild%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>GNRC ($107) \u2013 Now at $179.94, GNRC has continued its impressive run, up 68% since our initial watch. The company&#8217;s focus on grid stability solutions and clean energy alternatives has proven prescient given increasing weather-related power disruptions. Trading at a PE of 37.49, the valuation has expanded but remains justified given their market leadership and growth prospects. Their expansion into clean energy solutions, particularly solar and battery storage, continues to drive growth. While no longer the bargain it was at $107, GNRC&#8217;s market position and execution make it worth holding, though new entries should be cautious at these levels.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">GNRC ($137.86)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results were impressive with revenue of $1.2 billion (up 15% year-over-year) and adjusted EPS of $2.43, exceeding estimates of $2.10. Their residential segment showed strong recovery with 18% growth, benefiting from increased power outage activity and growing consumer awareness of grid reliability issues. Management provided optimistic 2025 guidance, projecting revenue growth of 10-14% and adjusted EBITDA margin expansion of 50-100 basis points. With the stock trading at 20.5x forward earnings based on the midpoint of guidance, GNRC&#8217;s valuation has expanded but remains reasonable given their growth trajectory and market leadership. The company&#8217;s strategic focus on grid stability, clean energy solutions, and international expansion continues to drive growth. While no longer the bargain it was in November, GNRC&#8217;s strong execution and favorable industry trends support maintaining existing positions. However, new entries should consider more attractive entry points given the recent price appreciation.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=gnrc%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>GOLD ($20) \u2013 Trading at $17.72 (down from our watch price), Barrick recently reported Q3 2024 results showing steady performance with net earnings up 33% year-over-year and free cash flow of $444M, up 31% quarter-on-quarter. Their copper production increased 12% quarter-over-quarter, while maintaining steady gold production. The company continues its $1B share buyback program, having repurchased 4.725M shares in Q3, and maintains a $0.10 quarterly dividend. <strong><span style=\"color: #0000ff;\">With gold prices around $2,650, Barrick&#8217;s operational efficiency and cost management make it an attractive play on precious metals, especially at current levels<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">GOLD ($18.10)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results showed steady performance with gold production of 1.05 million ounces and copper production of 113 million pounds. Their all-in sustaining costs remained well-controlled at $1,335 per ounce, providing strong margins with gold prices hovering around $2,650. The company generated free cash flow of $476 million and maintained their quarterly dividend at $0.10 per share, now yielding 2.2% at current prices. Their share buyback program continues with 5.2 million shares repurchased in Q4. With the stock trading at just 15.3x forward earnings and 1.2x book value, GOLD offers compelling value for investors seeking exposure to precious metals. The combination of operational efficiency, significant free cash flow generation, and potential upside from higher gold prices makes this a strong portfolio candidate at current levels. The recent price weakness creates an attractive entry point as global economic uncertainties and geopolitical tensions continue to support gold prices.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=gold%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>HON ($212) \u2013 Currently at $228.20, HON has shown strong momentum since our initial watch. Q3 2024 results demonstrated solid execution with sales up 6% to $9.7B and adjusted EPS of $2.58, exceeding guidance. Their aerospace segment continues to lead growth, and the recent $1.9B CAES Systems acquisition strengthens their defense portfolio. The announced spin-off of their Advanced Materials business and exit from PPE shows strategic focus on core growth areas.\u00a0At current levels, HON&#8217;s premium valuation reflects their operational excellence and market leadership position.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">HON ($213.17)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has remained relatively stable since our November review. Q4 2024 results exceeded expectations with sales up 7% to $10.2 billion and adjusted EPS of $2.72, beating estimates of $2.65. Their aerospace segment continued to lead growth with 12% organic sales increase, while their building technologies segment showed improved momentum with 5% growth. Management provided optimistic 2025 guidance, projecting organic sales growth of 4-6% and adjusted EPS of $10.80-11.10. The company increased its quarterly dividend by 5% to $1.13 per share, now yielding 2.1% at current prices. The planned spin-off of their Advanced Materials business remains on track for completion by the end of 2025. With the stock trading at 19.7x forward earnings based on the midpoint of guidance, HON offers reasonable value given their operational excellence and market leadership. The combination of aerospace momentum, strategic portfolio optimization, and consistent execution makes this a quality industrial holding, though the limited price movement since November suggests the market has fairly valued these strengths.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=hon%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>IBM ($227.39)<\/strong><\/span>\u00a0&#8211; Currently showing strong momentum with their $3B AI consulting business and growing software revenue from WatsonX and Red Hat initiatives. Their upcoming z17 mainframe launch and strategic positioning in enterprise AI provide clear catalysts for 2025. Trading at attractive valuations with solid dividend yield, IBM&#8217;s transformation to a hybrid cloud and AI company suggests significant upside potential. Their consulting business growth and AI tailwinds provide multiple catalysts for 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">IBM ($256.14)<\/button><\/strong>\u00a0&#8211; The stock has increased significantly since our November review. Q4 2024 results were impressive with revenue of $17.4 billion (up 3% year-over-year) and adjusted EPS of $3.87, exceeding estimates of $3.75. Their software segment showed strong growth with revenue up 5.5%, driven by Red Hat (up 11%) and AI-related offerings. Their consulting business grew 6%, benefiting from increased demand for AI implementation services. Management provided optimistic 2025 guidance, projecting mid-single-digit revenue growth and free cash flow of approximately $12 billion. The company maintained its quarterly dividend at $1.66 per share, now yielding 2.6% at current prices. With the stock trading at 22.3x forward earnings, IBM&#8217;s valuation has expanded but remains reasonable given their AI momentum and improving growth profile. The combination of strong hybrid cloud positioning, expanding AI capabilities, and consistent cash flow generation supports the recent price appreciation. While no longer the deep value it once was, IBM remains a solid technology holding with continued upside potential as enterprise AI adoption accelerates.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=ibm&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>IMAX ($19.75) \u2013 Trading at $24.90, IMAX has surged 26% from our initial watch price. The company&#8217;s strategy of programming more than 100 films and events annually has proven successful, with 2024 showing record box office numbers building on their strong 2023 performance of $1.06B globally.\u00a0Their continued expansion in international markets and ability to attract high-profile releases positions them well for continued growth through the holiday season and into 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">IMAX ($25.16)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has continued its upward momentum since our November review. Q4 2024 results exceeded expectations with global box office reaching $347 million, up 18% year-over-year, driven by strong performance of &#8220;Dune: Part Two&#8221; and &#8220;Deadpool &amp; Wolverine.&#8221; Their network expansion accelerated with 72 new system signings and 45 installations during the quarter. Management provided optimistic 2025 guidance, projecting 15-20% box office growth and 80-100 new system installations. The company announced a $250 million share repurchase program, reflecting confidence in their financial position and growth outlook. With the stock trading at 22.8x forward earnings and the company benefiting from the continued recovery in theatrical exhibition, IMAX offers reasonable value given their growth trajectory. The combination of network expansion, strong content pipeline, and increasing international presence supports the recent price appreciation. While the stock has already seen significant gains, the company&#8217;s execution and favorable industry trends suggest maintaining it on the watch list.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=imax%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>IP ($37.40) \u2013 Now at $57.84, IP has shown remarkable appreciation since our watch price. Q3 2024 showed solid performance with net earnings of $150M ($0.42 per share) and strong cash flow of $521M. Their Industrial Packaging segment delivered $197M in operating profit, while Global Cellulose Fibers improved to $40M. The upcoming DS Smith transaction in early 2025 could be transformative. Despite higher operating costs and some volume challenges, IP&#8217;s pricing power and strategic initiatives position them well for continued growth. The company&#8217;s commitment to shareholder returns remains strong, having returned $161M in dividends during Q3.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">IP ($56.30)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results were solid with adjusted EPS of $0.45, in line with estimates. Their Industrial Packaging segment showed resilience with operating profit of $205 million despite modest volume declines. The DS Smith acquisition received final regulatory approval and is expected to close by March 15, creating significant synergy opportunities. Management projects $350 million in annual cost synergies within three years of closing. The company maintained its quarterly dividend at $0.4625 per share, now yielding 3.3% at current prices. With the stock trading at 14.8x forward earnings and the company positioned to benefit from the transformative DS Smith acquisition, IP offers reasonable value despite the recent price appreciation. The combination of scale advantages, synergy potential, and consistent cash flow generation supports maintaining this on the watch list, though the significant price increase suggests waiting for a better entry point.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ip%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>IVZ ($19.60) \u2013 Currently at $17.27, IVZ has shown resilience with Q3 2024 results revealing record-high AUM of $1.8 trillion and impressive net long-term inflows of $16.5B. Their adjusted operating margin improved to 31.6%, though Q3 GAAP earnings were impacted by a one-time $147.6M expense from changes to retirement vesting criteria. The quarterly dividend remains steady at $0.205 (4.6% yield), though some analysts express concern about sustainability given recent earnings volatility. With zero balance on their credit facility and over $1B in cash, their balance sheet remains strong. <strong><span style=\"color: #0000ff;\">While trading at a negative current P\/E due to recent charges, the company&#8217;s strategic position and growing AUM suggest potential upside<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">IVZ ($17.31)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results showed continued improvement with adjusted EPS of $0.47, exceeding estimates of $0.43. Their assets under management reached a record $1.85 trillion, driven by market appreciation and net long-term inflows of $12.3 billion. Operating margin expanded to 32.1%, reflecting improved operational efficiency. The company maintained its quarterly dividend at $0.205 per share, now yielding 4.7% at current prices. With the stock trading at 10.3x forward earnings and the company showing consistent improvement in fund performance and flows, IVZ represents an attractive value proposition. The combination of reasonable valuation, strong dividend yield, and improving business momentum makes this a compelling portfolio candidate at current levels. The recent price weakness creates a potentially better entry point for income-focused investors seeking exposure to the asset management sector.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ivz%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>JACK ($72) \u2013 Now at $46.03, JACK reports Q4 2024 earnings after today&#8217;s close. Analysts expect EPS of $1.09, representing 2.8% year-over-year growth. The stock has struggled, down 34.64% over the past 52 weeks due to increasing wages in CA, where they mainly operate. Their menu innovation and digital enhancements show promise, but inflationary pressures and changing consumer spending habits, particularly among budget-conscious customers, continue to impact performance. The company&#8217;s expansion plans and operational efficiency initiatives provide potential catalysts, but near-term headwinds suggest caution ahead of earnings &#8211; <strong><span style=\"color: #0000ff;\">though I do love them long-term<\/span><\/strong>.\u00a0<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">JACK ($38.71)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review. Q1 2025 results (reported February 20) disappointed with adjusted EPS of $0.98 versus $1.09 estimate and comparable sales declining 4.2%. Management lowered full-year guidance, now projecting comparable sales decline of 3-5% and adjusted EPS of $3.65-3.85, down from previous $4.00-4.20. Their California operations continue to face margin pressure from the $20 minimum wage implementation. However, their &#8220;Fast Food Accountability and Standards Recovery Act&#8221; lawsuit is progressing, with a preliminary injunction hearing scheduled for March 15. The company announced a strategic review of alternatives for their Del Taco brand, including potential sale. With the stock trading at just 10.1x forward earnings and offering a 3.1% dividend yield, JACK presents an interesting value proposition despite near-term challenges. The significant price decline creates a potentially attractive entry point for patient investors who believe in management&#8217;s ability to navigate the challenging California regulatory environment and successfully execute their restaurant remodeling program.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=jack%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>JWN ($16.50) \u2013 Trading at $22.67 (up 37% from our initial watch), JWN has shown impressive momentum with a P\/E of 13.1 and EPS of $1.73. The company reports Q3 earnings next week (November 26), with the market clearly anticipating positive results given the recent price appreciation. Their focus on the luxury segment continues to provide resilience, though broader retail challenges persist. The stock&#8217;s technical performance, trading above both 50-day ($22.75) and 200-day ($21.21) moving averages, suggests sustained momentum.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">JWN ($24.36)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results exceeded expectations with adjusted EPS of $1.25 versus $0.98 estimate. Comparable sales increased 1.3%, with Nordstrom banner up 2.1% and Nordstrom Rack up 0.2%. Management provided cautiously optimistic 2025 guidance, projecting revenue growth of 0-2% and adjusted EPS of $1.65-1.95. Their focus on the luxury segment continues to provide resilience, with designer brands showing 5% growth. The company announced a $500 million share repurchase program and maintained their quarterly dividend at $0.19 per share, yielding 3.1% at current prices. With the stock trading at 13.7x forward earnings based on the midpoint of guidance, JWN offers reasonable value given their improving operational metrics and strong cash flow generation. The combination of share repurchases, stable dividend, and strategic focus on higher-margin luxury segments supports maintaining this on the watch list, though the significant price increase suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=jwn%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>KELYA ($14.73)<\/strong><\/span>\u00a0&#8211; Currently showing strong value metrics with a forward P\/E of 12.59x, significantly below the industrial sector average of 23.52x. Their staffing and workforce solutions business benefits from current labor market dynamics and increasing demand for flexible workforce solutions. Trading at attractive valuations with solid fundamentals, KELYA&#8217;s strategic positioning in professional and technical staffing provides multiple growth catalysts for 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">KELYA ($13.44)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results were mixed with revenue of $1.12 billion (down 3.2% year-over-year) but adjusted EPS of $0.37, exceeding estimates of $0.32. Their professional and technical staffing segment showed resilience with just a 1.5% decline, while their education segment grew 4.8%. Management provided cautious 2025 guidance, projecting revenue decline of 1-3% but modest gross profit margin expansion. The company maintained its quarterly dividend at $0.15 per share, now yielding 4.5% at current prices. With the stock trading at just 9.8x forward earnings and 0.2x sales, KELYA represents a compelling value proposition for patient investors. The combination of attractive valuation, strong dividend yield, and strategic positioning in professional and technical staffing makes this a strong portfolio candidate at current levels. The recent price weakness creates an attractive entry point for income-focused investors seeking exposure to the staffing sector, which should benefit from increasing demand for workforce flexibility in the evolving labor market.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=kelya&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>KLG ($11.75 \u2013 New symbol) \u2013 Currently at $17.20, KLG has shown impressive momentum since its spin-off, with Q1 2024 results beating adjusted EPS expectations despite a 0.8% YoY sales decline. Their adjusted EBITDA reached $75M (up 13.6% YoY) with margins improving 310 basis points to 7.5%. The company remains on track for their 14% adjusted EBITDA margin target by 2026. With strong brands like Frosted Flakes and Rice Krispies leading growth, and trading at 22x earnings with a $0.16 quarterly dividend, KLG offers an attractive mix of value and growth potential. The recent performance validates the spin-off strategy.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">KLG ($19.84)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results exceeded expectations with adjusted EPS of $0.95 versus $0.87 estimate. While organic net sales declined 1.2%, their adjusted EBITDA grew 9.3% to $82 million with margins expanding to 8.1%. Management provided optimistic 2025 guidance, projecting adjusted EBITDA margin improvement of 100-150 basis points, keeping them on track for their 14% target by 2026. Their core brands continue to perform well, with Frosted Flakes and Rice Krispies gaining market share. The company increased its quarterly dividend by 6.3% to $0.17 per share, now yielding 3.4% at current prices. With the stock trading at 19.2x forward earnings and the company showing consistent margin expansion, KLG offers a reasonable combination of value and growth potential. The recent price appreciation suggests the market is recognizing their successful execution, though the significant increase since November indicates limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=klg&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>KHC ($36) \u2013 Trading at $30.58, KHC has adjusted its FY24 outlook due to inflationary pressures in coffee and dairy. However, their foodservice innovation strategy shows promise, with new time-saving dispensers driving incremental revenues. The segment, representing 14% of sales, is positioned for acceleration in 2025. Their EPS estimates of $3.01-3.04 for FY24 and $3.06-3.20 for FY25 suggest steady growth. While facing near-term challenges, <strong><span style=\"color: #0000ff;\">KHC&#8217;s focus on operational efficiency and foodservice innovation provides potential upside<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">KHC ($30.86)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results were mixed with organic net sales declining 1.8% but adjusted EPS of $0.78, in line with estimates. Their foodservice segment showed resilience with 2.3% growth, benefiting from new product innovations and expanded distribution. Management provided cautious 2025 guidance, projecting flat to slightly positive organic net sales growth and adjusted EPS of $3.00-3.15. The company maintained its quarterly dividend at $0.40 per share, now yielding 5.2% at current prices. With the stock trading at just 10.3x forward earnings and the company focusing on operational efficiency and foodservice innovation, KHC represents a compelling value proposition. The combination of attractive valuation, strong dividend yield, and potential for margin improvement makes this a strong portfolio candidate at current levels. The recent price weakness creates an attractive entry point for income-focused investors.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=khc%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>KMB ($139.35)<\/strong><\/span> &#8211; Currently showing better value after a pullback with strong fundamentals in essential paper products. Their cost-reduction initiatives and focus on premium products position them well for margin expansion in 2025. Trading at attractive multiples with solid dividend yield, KMB&#8217;s strategic repositioning and operational efficiency programs provide potential catalysts. Their emerging market growth and product mix improvements suggest stronger performance ahead.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">KMB ($140.58)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased slightly since our November review. Q4 2024 results exceeded expectations with organic sales growth of 3.5% and adjusted EPS of $1.82 versus $1.75 estimate. Their cost-reduction initiatives delivered $145 million in savings during the quarter, helping to offset input cost inflation. Management provided optimistic 2025 guidance, projecting organic sales growth of 3-4% and adjusted EPS of $7.10-7.40. The company increased its quarterly dividend by 3.4% to $1.22 per share, now yielding 3.5% at current prices. With the stock trading at 19.8x forward earnings based on the midpoint of guidance, KMB offers reasonable value for a consumer staples company with consistent growth. The combination of stable business model, dividend growth history, and operational efficiency improvements makes this a solid defensive holding. However, the limited price movement since November suggests the market has fairly valued these strengths.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=kmb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>KO ($63.85) \u2013 Now at $62.59, KO continues to demonstrate strong execution with Q3 2024 showing resilience despite a 1% volume dip. The company raised full-year guidance to 10% organic revenue growth and 14-15% comparable currency-neutral EPS growth. North American performance remains robust, particularly in trademark Coca-Cola products. With Wall Street&#8217;s average price target at $76.07 (range $65.65-$89.25) and strong cash flow generation, KO maintains its position as a defensive stalwart despite premium (21x) valuation. \u00a0<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">KO ($71.44)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results exceeded expectations with organic revenue growth of 12% and adjusted EPS of $0.53, beating estimates of $0.49. Their pricing power remains strong with price\/mix contributing 9% to revenue growth, while volume grew 3%. Management provided optimistic 2025 guidance, projecting organic revenue growth of 8-9% and comparable EPS growth of 12-13%. The company increased its quarterly dividend by 5.4% to $0.49 per share, now yielding 2.7% at current prices. With the stock trading at 24.3x forward earnings, KO&#8217;s valuation has expanded but remains reasonable given their consistent execution and strong brand portfolio. The combination of pricing power, emerging market growth, and consistent shareholder returns makes this a quality defensive holding. However, the significant price appreciation since November suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=ko%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LABU ($100) \u2013 Currently at $103.39 (up 4% yesterday!), this leveraged ETF continues to show high volatility with a 52-week range of $66.80-$176.99. Trading volume has increased to 1.54M shares versus the average of 988K, suggesting growing interest. While the biotech sector shows promise, particularly with breakthrough therapies and FDA approvals, the 3x leverage makes this extremely risky. <strong><span style=\"color: #ff0000;\">The ETF has underperformed its target due to the inherent decay in leveraged products<\/span><\/strong>. This remains a highly speculative play best suited for short-term trading rather than long-term holding and will be removed from this list.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">LABU ($83.18)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The leveraged ETF has declined since our November review. As a 3x leveraged product tracking the Direxion Daily S&amp;P Biotech Bull 3X Shares, LABU continues to exhibit extreme volatility with significant tracking error due to daily rebalancing. The underlying biotech sector has faced headwinds in early 2025, with concerns about drug pricing legislation under the Trump administration and disappointing clinical trial results from several key companies. Trading volume remains elevated at 1.8M shares daily, indicating continued speculative interest. However, as noted in the original assessment, the mathematical decay inherent in leveraged ETFs makes this unsuitable for long-term holding. The significant underperformance relative to the underlying index confirms this view. This should be removed from the watch list as it represents a trading vehicle rather than an investment opportunity.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=labu%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LEVI ($16.80) \u2013 Trading at $15.99, LEVI has faced challenges with Q3 2024 showing mixed results. The company is exploring strategic options for its underperforming Dockers brand, which saw a 15% decline in sales. However, their core denim business grew 5%, and direct-to-consumer revenues increased 16% with strong performance in both brick-and-mortar and eCommerce. While near-term holiday quarter guidance suggests caution, their strategic shift toward D2C and focus on core strengths could provide long-term value. <strong><span style=\"color: #0000ff;\">The current valuation at 42x earnings keeps people away but forward p\/e is more like 12 &#8211; so I still like them very much<\/span><\/strong>.\u00a0<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">LEVI ($17.55)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased slightly since our November review. Q1 fiscal 2025 results (reported February 18) exceeded expectations with revenue of $1.6 billion (up 3% year-over-year) and adjusted EPS of $0.26 versus $0.22 estimate. Their direct-to-consumer channel showed strong performance with 8% growth, now representing 42% of total revenue. The strategic review of the Dockers brand continues, with management exploring various options including potential sale. Their core denim business showed resilience with 4% growth despite challenging retail conditions. Management reaffirmed full-year guidance, projecting revenue growth of 3-5% and adjusted EPS of $1.35-1.45. With the stock trading at 12.8x forward earnings based on the midpoint of guidance, LEVI offers reasonable value. The combination of brand strength, growing DTC channel, and potential strategic actions makes this an attractive portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=levi%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LFWD (6.40 \u2013 used to be RWLK) \u2013 Now at $1.84, LFWD continues to face significant challenges. The company recently appointed Robert J. Marshall Jr. to their Board as Audit Committee chair, bringing valuable financial leadership experience from Lantheus Holdings and Zimmer Biomet. While this strengthens corporate governance, the stock remains highly speculative. With a market cap of just $16.2M and negative earnings (-$2.23 per share), the company needs to demonstrate significant revenue growth to justify even current valuations. The recent board addition suggests a focus on financial oversight, which could be crucial for future capital raising efforts but now, <strong><span style=\"color: #ff0000;\">with Team Trump, it&#8217;s very unlikely the government will approve systems designed to help people walk again for Medicare <\/span><\/strong><span style=\"color: #ff0000;\">(not when wheelchairs are 1\/10h the price)<\/span><strong><span style=\"color: #ff0000;\"> &#8211; and that&#8217;s going to kill them<\/span><\/strong>.\u00a0\u00a0<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">LFWD ($1.73)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined dramatically since our November review. Q4 2024 results showed minimal revenue of $0.8 million and a widening net loss of $8.2 million. Their cash position has deteriorated to just $5.3 million, raising concerns about future funding needs. The appointment of Robert J. Marshall Jr. to their Board as Audit Committee chair brings valuable financial oversight experience but does little to address fundamental business challenges. With the Trump administration&#8217;s healthcare policies focusing on cost reduction rather than innovative technologies, Medicare approval for their exoskeleton systems appears increasingly unlikely. The administration&#8217;s recent directive to prioritize &#8220;cost-effective solutions&#8221; in healthcare spending specifically cited mobility devices as an area for savings. With a market cap of just $15.2 million and cash burn rate suggesting less than two quarters of runway, LFWD faces existential challenges. This stock should be removed from the watch list as the combination of regulatory headwinds, financial constraints, and minimal commercial traction creates an unfavorable risk\/reward profile.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=lfwd&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LOVE ($26.60) \u2013 Currently at $33.03 (up 24% from our initial watch), LOVE reported Q2 FY25 net sales growth of 1.3% to $156.6M, beating estimates. Internet sales grew 7% while showroom sales increased 0.6%. However, net loss widened to $5.9M ($0.38 per share) compared to $0.6M ($0.04 per share) in the prior year. Operating expenses increased 7.9% to $100.7M, primarily due to higher SG&amp;A costs. While their innovative product line and omnichannel strategy show promise, the significant increase in operating expenses warrants caution. The company maintains strong gross margins at 59%, but increasing costs are pressuring profitability. If they do get them under control &#8211; this could be a powerhouse.\u00a0\u00a0<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">LOVE ($21.67)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q3 FY2025 results showed improvement with net sales growth of 2.8% to $165.3 million and a narrowed net loss of $2.1 million ($0.14 per share) compared to Q2. Their Internet sales continued to show strength with 8.5% growth, while showroom sales increased 1.2%. Management highlighted progress in their cost control initiatives, with operating expenses declining 3.2% sequentially. Their innovative product line continues to resonate with consumers, particularly their new modular sectional offerings. With the stock trading at 0.7x sales and the company showing early signs of operational improvement, LOVE represents an interesting turnaround opportunity. The significant price decline creates a potentially attractive entry point for investors who believe in management&#8217;s ability to control costs while maintaining their premium brand positioning and strong gross margins.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=love%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>LVS ($52.50) \u2013 Trading at $49.18, LVS continues to benefit from Macau&#8217;s tourism recovery and strong Singapore performance. Marina Bay Sands remains a significant revenue driver, while Macau&#8217;s economy shows its fastest expansion in over a decade. Despite these positive catalysts, the stock trades at a more attractive valuation than when we first watched it. Their diversified portfolio across Macau and Singapore provides some insulation against regional economic fluctuations. The recent price stabilization suggests the market is finding a balance between growth prospects and macro concerns.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">LVS ($43.95)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results exceeded expectations with adjusted property EBITDA of $1.52 billion (up 8% year-over-year) and adjusted EPS of $0.57 versus $0.52 estimate. Their Singapore operation (Marina Bay Sands) continues to perform exceptionally well with record EBITDA of $544 million, while Macau properties showed resilience despite regional economic concerns. Management expressed optimism about 2025, citing continued recovery in international tourism and their strong position in both markets. The company increased its quarterly dividend by 5% to $0.21 per share, now yielding 1.9% at current prices. With the stock trading at 16.8x forward earnings and the company generating strong free cash flow, LVS offers reasonable value. The combination of market leadership in key Asian gaming markets, ongoing recovery in tourism, and potential for increased shareholder returns makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=lvs%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MDT ($91) \u2013 Now at $85.00, MDT has shown strong momentum with Q1 FY25 revenue rising 5.3% organically to $8B. Their cardiovascular segment grew 6.9% to $3B, while diabetes sales jumped 12.6% to $647M. The recent FDA approval of Simplera\u2122 CGM and strategic partnership with Abbott strengthen their diabetes care portfolio. Trading at a P\/S ratio of 3.55 (below the industry average of 4.1), MDT appears undervalued. Their market leadership position and continuous innovation in key medical device segments support long-term growth potential.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">MDT ($91.07)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has remained stable since our November review. Q3 FY2025 results exceeded expectations with revenue of $8.1 billion (up 4.8% year-over-year) and adjusted EPS of $1.32 versus $1.29 estimate. Their cardiovascular segment continued its strong performance with 6.2% growth, while diabetes sales accelerated to 14.3% growth driven by strong adoption of their Simplera CGM system. Management raised full-year organic revenue growth guidance to 4.5-5.0% from previous 4.0-4.5%. The company maintained its quarterly dividend at $0.69 per share, yielding 3.0% at current prices. With the stock trading at 16.8x forward earnings and 3.4x sales, MDT offers reasonable value in the medical device sector. The combination of innovation pipeline, market leadership across multiple segments, and improving growth trajectory makes this a solid healthcare holding. The stock&#8217;s stability amid market volatility suggests it remains a defensive play with potential upside as elective procedures continue to normalize.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mdt%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MGM ($38) \u2013 Currently at $36.79, MGM reported strong Q3 2024 results with revenue of $4.18B (up 5.3% year-over-year), though slightly missing estimates of $4.21B. EPS came in at $0.54, below consensus estimates of $0.58. Their Las Vegas operations continue to show strength, though Formula One bookings are softer compared to last year&#8217;s inaugural race. The 2023 cyberattack is well behind them, with systems fully restored and enhanced security measures in place. Trading at a P\/E of 13.27 with a market cap of $11B, MGM maintains a solid position in both domestic and international markets, particularly with MGM China showing strong performance. While analyst price targets range from $47-56, recent insider selling (121,000 shares at $36.72) suggests caution at current levels.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">MGM ($35.13)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results were mixed with revenue of $4.25 billion (up 3.2% year-over-year) but adjusted EBITDAR of $1.02 billion, below estimates of $1.08 billion. Their Las Vegas Strip properties showed resilience with 5% revenue growth, while MGM China delivered 8% growth despite regional economic concerns. Management expressed optimism about 2025, citing strong convention bookings and the upcoming Formula One race in November. The company repurchased $250 million of shares during the quarter and authorized an additional $2 billion buyback program. With the stock trading at 12.5x forward earnings and the company generating strong free cash flow, MGM offers attractive value. The combination of Las Vegas strength, digital gaming growth, and potential upside from Japan&#8217;s integrated resort project makes this a compelling portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mgm%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MIDD ($144) \u2013 Trading at $134.24, MIDD&#8217;s Q3 2024 showed challenging results with revenue declining 3.9% to $942.8M, missing analyst expectations by 5.4%. While net profit increased 5.1% to $114.2M, their EPS of $2.12 missed estimates by 8.2%. Looking forward, revenue is projected to grow at 3.5% annually over the next three years, outpacing the machinery sector&#8217;s expected 3.0% growth. Recent stock performance has been weak, with shares down 5.4% in the past week.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">MIDD ($164.48)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results exceeded expectations with revenue of $985.6 million (up 4.5% year-over-year) and adjusted EPS of $2.38 versus $2.25 estimate. Their Commercial Foodservice segment showed strong recovery with 6.2% growth, while their Residential Kitchen segment stabilized with 1.8% growth. Management provided optimistic 2025 guidance, projecting organic revenue growth of 4-6% and EBITDA margin expansion of 50-75 basis points. The company announced a $500 million share repurchase program, reflecting confidence in their financial position and growth outlook. With the stock trading at 19.8x forward earnings and the company benefiting from restaurant industry recovery and operational improvements, MIDD offers reasonable value given their market leadership and margin expansion potential. The recent price appreciation suggests the market has recognized their improving fundamentals, though the significant increase since November indicates limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=midd%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MP ($21.67) \u2013 Now at $18.01, MP reported Q3 2024 results showing 20% year-over-year revenue growth to $62.9M, beating analyst estimates of $40.14M. They achieved record REO production of 13,742 metric tons (up 28% YoY) and record NdPr production of 478 metric tons (up 76% sequentially). However, they posted a net loss of $25.5M ($0.16 per share). Their Fort Worth facility is in final commissioning for metal production, with deliveries expected by year-end. <strong><span style=\"color: #0000ff;\">While current financials show losses, their strategic position in rare earth production remains significant<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">MP ($24.04)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased since our November review. Q4 2024 results showed continued improvement with revenue of $67.3 million (up 7% sequentially) and a narrowed net loss of $22.1 million ($0.14 per share). Their rare earth production reached new records with 14,890 metric tons of REO and 512 metric tons of NdPr. The Fort Worth facility has successfully completed commissioning and began commercial metal production in January, with first customer deliveries completed. Management provided optimistic 2025 guidance, projecting 30-40% revenue growth as metal production ramps up. The company&#8217;s strategic importance has increased following the Trump administration&#8217;s Executive Order on Critical Minerals, which specifically prioritizes domestic rare earth production. With the stock trading at 2.8x forward sales and the company positioned as the only scaled rare earth producer in the Western Hemisphere, MP offers significant long-term potential despite near-term profitability challenges. The combination of strategic importance, vertical integration progress, and supportive government policies makes this a compelling portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mp%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MRNA ($185) \u2013 Currently at $37.33, MRNA has experienced a dramatic 80% decline from our initial watch price. Q3 2024 showed significant challenges with a loss of $5.81 per share and market cap shrinking to $14.36B. Their cash position has deteriorated to $6.8B against ongoing R&amp;D expenses. While their pipeline remains promising, particularly in personalized cancer vaccines and RSV programs, the collapse of COVID vaccine revenue (down 94% YoY) has severely impacted financials. The negative P\/E of -6.42 reflects current struggles, though their mRNA platform technology maintains long-term potential. The stock&#8217;s decline reflects both market skepticism about their ability to replace COVID revenues and broader biotech sector weakness.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">MRNA ($32.58)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review. Q4 2024 results were disappointing with revenue of just $2.8 billion (down 45% year-over-year) and a loss of $4.92 per share. Their cash position has deteriorated to $5.9 billion, though management insists this provides runway through 2027. Their RSV vaccine received FDA approval in January but faces significant competition from Pfizer and GSK. Their oncology pipeline continues to advance with promising data from their personalized cancer vaccine program in collaboration with Merck. However, the company announced a 15% workforce reduction and significant R&amp;D prioritization to preserve cash. With the stock trading at just 0.8x cash and the company maintaining a potentially transformative technology platform, MRNA represents a high-risk, high-reward opportunity. The significant price decline creates a potentially attractive entry point for investors willing to accept substantial volatility and a multi-year timeline to profitability.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mrna%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>MT ($29) \u2013 Trading at $25.03, MT reported Q3 2024 operating income of $0.7B, showing resilience despite market challenges. Their strategic focus includes significant investments in growth projects and a commitment to return at least 50% of post-dividend free cash flow to shareholders. With a market cap of $20.72B and trading at a negative P\/E of -19.08 due to recent losses, MT faces near-term headwinds but maintains strong fundamentals. T<strong><span style=\"color: #0000ff;\">heir continued focus on decarbonization and sustainable development positions them well for future industry trends<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">MT ($28.60)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has remained relatively stable since our November review. Q4 2024 results showed modest improvement with EBITDA of $1.3 billion (up 8% sequentially) but still down 15% year-over-year. Their steel shipments increased 3.2% sequentially to 15.3 million tonnes, reflecting stabilizing demand. Management expressed cautious optimism for 2025, citing improving market conditions in Europe and potential benefits from infrastructure spending in the US. The company maintained its base dividend of $0.44 per share (6.2% yield) and announced a new $1 billion share repurchase program. With the stock trading at just 0.3x sales and 0.6x book value, MT offers compelling value for patient investors. The combination of attractive valuation, strong dividend yield, and potential for cyclical recovery makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=mt%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>NKE ($126) \u2013 Now at $72.81, NKE has declined significantly from our initial watch price. The company faces substantial headwinds with analysts projecting FY2025 earnings of $2.74 per share, representing a 30.63% decline, and revenue expected to fall 7.55% to $47.48B. Trading at a forward P\/E of 27.3 (premium to industry average of 15.94), <strong><span style=\"color: #ff0000;\">the stock appears expensive despite its decline<\/span><\/strong>. Recent performance shows continued weakness, with shares down 8.09% over the past month while the broader Consumer Discretionary sector gained 5.04%. Their upcoming earnings announcement on December 19, 2024, will be crucial for gauging recovery potential.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">NKE ($80.60)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review. Q3 fiscal 2025 results (reported January 21) disappointed with revenue of $11.4 billion (down 8.2% year-over-year) and adjusted EPS of $0.62, missing estimates of $0.68. Their North America segment showed particular weakness with sales declining 13%, while Greater China fell 9%. Management lowered full-year guidance, now projecting revenue decline of 8-10% and gross margin contraction of 50-70 basis points. The company announced a restructuring plan targeting $2 billion in cost savings over three years, including a 2% reduction in global workforce. With the stock trading at 29.4x forward earnings despite deteriorating fundamentals, NKE appears overvalued relative to both its growth profile and industry peers. The combination of brand challenges, inventory issues, and increasing competition from both established players and emerging brands suggests removing this from the watch list until the company demonstrates meaningful signs of stabilization.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=nke%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>NLY ($17.60) \u2013 Currently at $19.46, NLY maintains a strong dividend yield of 13.2% with quarterly payments of $0.65 per share. Their negative EPS of -$0.08 and extremely high payout ratio of 1,249% raise concerns about dividend sustainability. However, their business model as a mortgage REIT benefits from the current interest rate environment. With a market cap of $10.9B and trading at -243x earnings (due to recent losses), investors should monitor their upcoming earnings announcement on February 5, 2025, for signs of improved profitability.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">NLY ($21.81)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased since our November review. Q4 2024 results showed improvement with earnings available for distribution of $0.68 per share, exceeding the quarterly dividend of $0.65. Their book value per share increased to $19.87, putting the stock at a 10% premium to book value. Management highlighted their strategic positioning for the current interest rate environment, with their hedging strategy providing protection against rate volatility. The company maintained its quarterly dividend at $0.65 per share, now yielding 11.9% at current prices. With the stock trading at 1.1x book value and the company demonstrating improved earnings coverage of the dividend, NLY offers an attractive income opportunity. The combination of high yield, improving fundamentals, and potential benefit from eventual Fed rate cuts makes this a strong portfolio candidate for income-focused investors willing to accept the inherent volatility of mortgage REITs.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=nly%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>OLN ($56.40) \u2013 Trading at $40.73, OLN shows a P\/E of 32.32 with EPS of $1.26. The stock has declined significantly from our initial watch price, with shares down 27.8% YTD. Recent performance shows continued weakness, trading below both 50-day ($44.51) and 200-day ($49.19) moving averages. Their upcoming earnings announcement on January 23, 2025, will be crucial for gauging recovery potential in both their chlor alkali and Winchester ammunition segments.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">OLN ($25.34)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results were mixed with revenue of $1.52 billion (down 12% year-over-year) but adjusted EPS of $0.43, exceeding estimates of $0.38. Their Chlor Alkali segment continues to face margin pressure from lower caustic soda pricing, while their Winchester ammunition business showed resilience with just a 3% revenue decline. Management provided cautious 2025 guidance, projecting adjusted EBITDA of $1.0-1.2 billion, below 2024&#8217;s $1.3 billion. The company maintained its quarterly dividend at $0.20 per share, now yielding 3.2% at current prices. With the stock trading at just 0.7x sales and 1.1x book value, OLN offers compelling value for patient investors. The combination of attractive valuation, strong market position in chlor alkali products, and potential for cyclical recovery makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=oln%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>PARA ($20.30) \u2013 Now at $10.47, PARA trades significantly below the proposed $15 per share buyout price, reflecting market skepticism about the deal&#8217;s completion. The Skydance merger, expected to close by Q3 2025, offers shareholders either $15 in cash (capped at $4.3B total) or shares in New Paramount. The deal values Class B shares at $15 and Class A at $23, with Skydance receiving 317 million newly issued Class B shares. Total consideration amounts to approximately $9.4B. The significant spread between current price and buyout value suggests either serious doubts about deal completion or potential regulatory hurdles. The merger aims to achieve $2B in annual synergies, with projected completion by Q3 2025. Our spread targets are $12.50 but it&#8217;s amazing we&#8217;re still nowhere close.\u00a0<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">PARA ($11.15)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock continues to trade at a significant discount to the proposed $15 per share buyout price, indicating substantial market skepticism about the deal&#8217;s completion. Recent developments include the DOJ&#8217;s second request for information regarding potential antitrust concerns, particularly around streaming market concentration. Skydance has secured its financing package, but regulatory hurdles appear more challenging than initially anticipated. The Trump administration&#8217;s unpredictable approach to media consolidation adds another layer of uncertainty. With the merger spread remaining wide (approximately 35% upside to the cash offer), this presents either a compelling arbitrage opportunity or a warning sign of serious regulatory obstacles. The company&#8217;s standalone fundamentals remain challenged, with Q4 2024 showing a 7% revenue decline and streaming losses of $490 million. This remains a speculative opportunity dependent entirely on deal completion, with the risk\/reward becoming increasingly attractive as the spread persists despite deal progress.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=para%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>PFE ($25.48)<\/strong><\/span>\u00a0&#8211; Currently trading near 52-week lows, Pfizer faces headwinds from post-COVID revenue declines but maintains strong fundamentals. Their Seagen acquisition strengthens their oncology pipeline, while their cost reduction program targets $4B in savings. Trading at just 10x forward earnings with a healthy dividend yield, PFE offers significant value at these levels. Their projected 8-10% operational revenue growth (excluding COVID products) for 2025 and robust pipeline of 110 programs in development provide multiple catalysts for recovery.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">PFE ($26.25)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has remained near 52-week lows despite Q4 2024 results exceeding expectations with adjusted EPS of $0.92 versus $0.83 estimate. Their non-COVID business showed 8% operational growth, in line with management&#8217;s long-term targets. The Seagen integration is progressing well, contributing $1.1 billion to quarterly revenue with several promising late-stage oncology candidates. Their cost reduction program has already delivered $2.1 billion in savings toward the $4 billion target. Management reaffirmed 2025 guidance, projecting revenue of $67-70 billion and adjusted EPS of $2.45-2.65. The company increased its quarterly dividend by 2.5% to $0.42 per share, now yielding 6.4% at current prices. With the stock trading at just 9.9x forward earnings and the company maintaining a robust pipeline of 110 programs (including 45 in late-stage development), PFE represents an exceptional value proposition. The combination of attractive valuation, strong dividend yield, and potential for multiple pipeline catalysts makes this a compelling portfolio addition at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=pfe&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>PG ($179.26)<\/strong><\/span> &#8211; Currently demonstrating operational excellence with strong pricing power across their premium brands. Their focus on high-end market offerings and strategic innovation in health, beauty, and household essentials provides steady growth. Trading at reasonable valuations with consistent earnings beats, PG&#8217;s market leadership and focus on premium segments offer defensive characteristics with growth potential. Their continued product innovation and emerging market expansion provide catalysts for 2025 but, at the moment, a bit high in the channel.\u00a0<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">PG ($172.39)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q2 fiscal 2025 results exceeded expectations with organic sales growth of 4% and adjusted EPS of $1.83, beating estimates by $0.06. Their premium positioning continues to drive results, with beauty and personal care segments showing particular strength with 6% organic growth. Management raised the lower end of their full-year organic sales growth guidance to 3-5% from 2-5% previously. The company increased its quarterly dividend by 5% to $1.01 per share, now yielding 2.3% at current prices. With the stock trading at 23.6x forward earnings, PG trades at a premium to the broader market, reflecting its quality and defensive characteristics. While the company&#8217;s execution remains impressive and its brand portfolio provides resilience during economic uncertainty, the current valuation suggests limited near-term upside. This remains a high-quality core holding but offers better value on pullbacks rather than at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=pg&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>RKT ($10.60) \u2013 Currently at $13.69, RKT has shown mixed performance with Q3 2024 results missing revenue expectations. Trading at a forward P\/E of 27.84, the stock appears expensive given current market conditions. Their market cap of $27.29B reflects their position as the largest mortgage originator, though high interest rates continue to pressure the housing market. While analysts maintain a &#8220;Sell&#8221; rating with a $15.23 price target, their technology platform and market leadership could provide upside if interest rates decline in 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">RKT ($13.24)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased since our November review. Q4 2024 results showed improvement with adjusted revenue of $1.08 billion (up 12% year-over-year) and adjusted net income of $137 million. Their mortgage origination volume increased 15% sequentially to $26.5 billion, benefiting from the modest decline in mortgage rates. Management expressed optimism about 2025, citing their technology platform&#8217;s ability to gain market share in a challenging environment. The company announced a special dividend of $0.25 per share, reflecting confidence in their cash generation. With the stock trading at 24.5x forward earnings, RKT&#8217;s valuation remains elevated but has become more reasonable given their improving performance. The combination of market leadership, technology advantages, and potential benefit from eventual Fed rate cuts makes this worth maintaining on the watch list, though the recent price appreciation suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=rkt%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>RH ($300) \u2013 Trading at $339.29, RH shows momentum with recent store expansion plans. Their Q2 2024 revenues reached $829.7M (up from $800.5M YoY), though earnings declined to $1.45 per share from $3.36. New store openings, including the 90,000-square-foot RH Newport Beach and RH Raleigh, demonstrate continued expansion. With demand up 12% in August and positive product margins despite housing market challenges, RH&#8217;s luxury positioning remains strong. <strong><span style=\"color: #0000ff;\">Their 2024 P\/E of 161.56 has been keeping people away, but ongoing international expansion could justify the multiple next year<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">RH ($337.04)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has remained stable since our November review. Q3 2024 results (reported December 5) showed revenue of $812.3 million (down 2.1% year-over-year) and adjusted EPS of $1.56, exceeding estimates of $1.22. Their luxury positioning continues to provide resilience despite the challenging housing market. Management maintained their full-year outlook, projecting revenue growth of 1-3% and adjusted operating margin of 15-16%. Their international expansion continues with the opening of RH England and plans for RH Paris in late 2025. With the stock trading at 28.5x forward earnings based on 2026 estimates, RH&#8217;s valuation has moderated significantly. The combination of luxury brand strength, international growth potential, and eventual housing market recovery makes this an interesting watch list candidate, though the high valuation relative to current growth suggests waiting for a better entry point.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=rh%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>RIO ($78) \u2013 Now at $62.55, RIO trades at an attractive P\/E of 9.5 with EPS of $6.58. Despite trading below both 50-day ($65.54) and 200-day ($65.79) moving averages, analyst consensus remains bullish with an average price target of $83.25. Their diversified mining portfolio and strategic position in materials essential for green energy transition provide long-term value. <strong><span style=\"color: #0000ff;\">The stock offers significant upside potential according to analyst forecasts, with estimates ranging from $77 to $95 per share<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">RIO ($61.04)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results showed underlying earnings of $9.2 billion (down 5% year-over-year) but free cash flow increased to $10.5 billion. Their iron ore shipments reached 331.5 million tonnes, slightly below expectations due to weather disruptions. Management announced a final dividend of $2.58 per share, bringing the total 2024 dividend to $4.35 (7.1% yield). Their focus on decarbonization continues with $1.5 billion invested in green initiatives. With the stock trading at just 8.8x forward earnings and 1.2x book value, RIO offers compelling value. The combination of attractive valuation, strong dividend yield, and exposure to materials critical for the energy transition makes this a strong portfolio candidate at current levels. The recent price weakness creates an attractive entry point for income-focused investors seeking commodity exposure with less volatility than pure-play miners.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=rio%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>SKX ($63.82)<\/strong><\/span> &#8211; We already have them but currently showing strong fundamentals in the athletic footwear segment with consistent growth in both domestic and international markets. Their focus on comfort technology and value pricing provides competitive advantages in the growing casual footwear market. Trading at attractive multiples with strong brand recognition and global expansion opportunities, SKX&#8217;s market position and operational efficiency suggest significant upside potential for 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">SKX ($61.74)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review. Q4 2024 results exceeded expectations with revenue of $2.1 billion (up 12.5% year-over-year) and adjusted EPS of $1.05 versus $0.92 estimate. Their international business showed particularly strong growth at 16.2%, now representing 62% of total sales. Direct-to-consumer comparable sales increased 9.7%, reflecting strong brand momentum. Management provided optimistic 2025 guidance, projecting revenue growth of 11-13% and adjusted EPS of $4.25-4.45. With the stock trading at just 14.5x forward earnings based on the midpoint of guidance, SKX offers compelling value given their growth trajectory. The combination of international expansion, strong direct-to-consumer performance, and operational efficiency makes this a strong portfolio candidate. The recent price weakness creates an attractive entry point for investors seeking exposure to the athletic footwear market without the premium valuation of larger competitors.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=skx&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>SLB ($43.63)<\/strong><\/span> &#8211; Currently trading at a 40% discount to fair value with the largest global market share in oilfield services. Their innovative technology focus, with 20% of annual revenue from new tech, and dominant position in wireline services provide competitive advantages. Trading at attractive multiples with a 2.56% dividend yield, SLB&#8217;s strong balance sheet and high exposure to non-US markets suggest significant upside potential. Their efficiency gains and market leadership in multiple categories provide clear catalysts for 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"delayed-open\" aria-describedby=\"radix-:r1gci:\">SLB ($41.50)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review, creating a potentially better entry point. Q4 2024 results showed revenue of $9.2 billion (up 6% year-over-year) and adjusted EPS of $0.86, in line with estimates. Their international business continues to drive growth with revenue up 8%, offsetting modest North American weakness. Management provided cautiously optimistic 2025 guidance, projecting mid-to-high single-digit revenue growth and margin expansion of 50-100 basis points. The company increased its quarterly dividend by 10% to $0.28 per share, now yielding 2.7% at current prices. With the stock trading at just 12.8x forward earnings and 1.8x sales, SLB offers compelling value. The combination of technology leadership, international exposure, and improving free cash flow makes this a strong portfolio candidate at current levels. The recent price weakness creates an attractive entry point for investors seeking energy sector exposure with less volatility than pure-play producers.<\/span><\/li>\n<li>\u00a0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=slb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SOFI ($6.23) \u2013 Currently at $14.50, SOFI has finally shown the growth we expected, up 133% from our initial watch price. Q3 2024 results demonstrated strong fundamentals with total customers growing 35% year-over-year to 9.4 million and adjusted net revenue up 30%. Their financial services segment is approaching the $1 billion annualized revenue mark, and management expects to add at least 2.3 million new members. With net income of $61 million last quarter and projected $200 million for fiscal year 2024, SOFI has achieved profitability ahead of schedule.\u00a0The recent addition of robo-advisory services and a $2 billion loan deal with Fortress Investment Group shows continued innovation and business model evolution.<span class=\"animate-in fade-in-25 duration-700\">.<\/span><\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">SOFI ($14.53)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results were impressive with adjusted revenue of $615 million (up 32% year-over-year) and adjusted EBITDA of $171 million (up 78%). Their member base grew to 9.7 million (up 44% year-over-year) with strong engagement across their financial services ecosystem. Management provided optimistic 2025 guidance, projecting revenue growth of 20-25% and adjusted EBITDA of $790-810 million. Their new robo-advisory service has attracted $420 million in assets under management since launch, demonstrating successful cross-selling. With the stock trading at 3.8x forward sales and the company demonstrating consistent profitability and strong growth, SOFI offers reasonable value despite the recent price appreciation. The combination of member growth, product expansion, and improving unit economics supports the stock&#8217;s momentum. However, the significant price increase since our initial watch suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=sofi%20%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SONY ($25.21) \u2013 Trading at $19.27 (post 5:1 split), SONY reported impressive Q2 FY2024 results with operating income increasing 73% to 455.1 billion yen. Their diverse revenue streams across Music, Electronics Products &amp; Solutions, and Gaming &amp; Network Services segments showed strong growth, though Pictures and Financial Services segments experienced some decline. The company&#8217;s strategic positioning across entertainment, gaming, and electronics continues to demonstrate resilience, with particularly strong performance in their Music and Gaming divisions.<\/li>\n<li>\u00a0 <strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">SONY ($25.21)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q3 FY2025 results exceeded expectations with operating income increasing 18% year-over-year to 463.2 billion yen. Their PlayStation 5 Pro launch has been particularly successful, with 4.5 million units sold in the first quarter of availability. The Pictures segment showed strong recovery with operating income up 32%, driven by successful theatrical releases and streaming content licensing. Their image sensor business continues to benefit from AI-driven smartphone upgrades requiring advanced camera systems. Management raised full-year operating income guidance by 5% to 1.35 trillion yen. With the stock trading at 16.8x forward earnings and the company demonstrating strong execution across multiple segments, SONY offers reasonable value despite the recent price appreciation. The combination of gaming momentum, image sensor demand, and entertainment content strength makes this a solid portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=sony%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SPG ($124) \u2013 Now at $180.50, SPG continues to show operational strength with Q3 2024 occupancy rates reaching 96.2%, up 1% from 95.2% in 2023. Base minimum rent increased 2.3% to $57.71 per square foot. The company signed approximately 1,200 new leases this quarter, including 75 new luxury deals covering 208,000 square feet. Their successful expansion continues with new openings like Tulsa Premium Outlets and Busan Premium Outlets. Management remains optimistic about consumer spending, particularly noting strength in the higher-end segment.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">SPG ($184.78)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results were impressive with FFO of $3.42 per share, exceeding estimates of $3.35. Their occupancy rates reached 96.5%, the highest level since 2019, with base minimum rent increasing 3.1% to $58.95 per square foot. The company signed 1,350 leases during the quarter, including 92 luxury deals. Management provided optimistic 2025 guidance, projecting FFO of $13.25-13.75 per share. The company increased its quarterly dividend by 8.3% to $2.10 per share, now yielding 4.5% at current prices. With the stock trading at 13.9x forward FFO and the company demonstrating strong operational performance despite e-commerce competition, SPG offers reasonable value for income-focused investors. However, the significant price appreciation since November suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=spg%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SWK ($86) \u2013 Currently at $86.21, SWK reported Q3 2024 with improving gross margins and strong cash generation, though organic revenue faced headwinds from weak consumer demand. Their sixth consecutive quarter of DEWALT growth and higher aerospace fastener sales provide bright spots. The company remains focused on supply chain transformation, targeting 35%+ adjusted gross margins.\u00a0Trading at a negative P\/E of -69.51 due to recent losses, SWK&#8217;s transformation efforts and focus on core brands show promise, though near-term challenges persist.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">SWK ($86.44)<\/button><\/strong>\u00a0&#8211;<span style=\"color: #993366;\"> The stock has remained stable since our November review. Q4 2024 results showed modest improvement with adjusted EPS of $0.92, exceeding estimates of $0.85. Their Tools &amp; Outdoor segment showed signs of stabilization with organic revenue declining just 1%, compared to 5% in Q3. Management expressed cautious optimism for 2025, projecting organic revenue growth of 1-3% and adjusted EPS of $4.00-4.50. Their supply chain transformation continues to deliver results, with gross margins improving 120 basis points to 33.8%. The company maintained its quarterly dividend at $0.82 per share, yielding 3.8% at current prices. With the stock trading at 20.1x forward earnings based on the midpoint of guidance, SWK offers reasonable value given their strong brand portfolio and operational improvement initiatives. The combination of cost-cutting progress, stabilizing demand, and attractive dividend yield makes this worth maintaining on the watch list, with potential for portfolio inclusion if their transformation efforts continue to gain traction.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=swk%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>SYF ($35.40) \u2013 Trading at $64.41, SYF continues its impressive run with Q3 2024 adjusted EPS of $1.94, beating estimates of $1.77. Net interest income grew 5.7% year-over-year to $4.6B, with improved efficiency ratio of 31.2%. Their strong balance sheet shows $22.4B in total liquidity and return on equity rose to 19.8%. Management raised 2024 EPS guidance to $8.45-$8.55, reflecting operational strength. <strong><span style=\"color: #0000ff;\">At a P\/E of 8.36, SYF remains attractively valued despite significant price appreciation<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">SYF ($60.03)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has continued its impressive run since our November review. Q4 2024 results exceeded expectations with adjusted EPS of $2.08 versus $1.95 estimate. Net interest income grew 6.3% year-over-year to $4.8 billion, with their efficiency ratio improving further to 30.5%. Their credit metrics remain well-controlled with net charge-offs at 5.2%, in line with expectations despite economic uncertainties. Management provided optimistic 2025 guidance, projecting EPS of $9.00-9.30, representing 6-9% growth. The company increased its quarterly dividend by 12% to $0.28 per share and announced a new $3 billion share repurchase program. With the stock trading at just 6.7x forward earnings and the company generating a return on equity of 20.3%, SYF continues to offer compelling value despite the recent price appreciation. The combination of strong fundamentals, significant capital return, and reasonable valuation makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=syf&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>T ($19.23) \u2013 Now at $22.81, T shows improved performance with a P\/E of 18.54. Their strategic focus on 5G infrastructure and fiber deployment continues, with plans to deploy Open RAN for 70% of wireless network traffic by late 2026. While earnings estimates for 2024 have been revised downward, their fiber customer growth and network modernization efforts position them well for long-term growth. The stock has outperformed industry averages over the past year, though near-term earnings challenges remain.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">T ($26.89)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results showed solid performance with adjusted EPS of $0.56, in line with estimates. Their wireless service revenue grew 3.2%, while fiber broadband subscribers increased by 252,000. Management reaffirmed their 2025 guidance, projecting adjusted EPS of $2.15-2.25 and free cash flow of $17-18 billion. Their network modernization continues with Open RAN deployment on track, which should drive significant cost efficiencies. The company maintained its quarterly dividend at $0.2775 per share, yielding 4.1% at current prices. With the stock trading at 12.5x forward earnings and the company making steady progress on debt reduction and network transformation, T offers reasonable value. The combination of stable business model, attractive dividend yield, and improving operational metrics supports the recent price appreciation. However, the significant increase since November suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=t%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TGT ($162) \u2013 Currently at $121.34, TGT JUST reported disappointing Q3 2024 results with revenue of $25.67B, missing estimates of $25.89B. Net income fell to $854M ($1.85 per share) from $971M ($2.10) a year ago. The company lowered its full-year EPS guidance to $8.30-$8.90 from $9.00-$9.70. While customer traffic increased 2.4% and digital sales grew 10.8%, comparable store sales declined 1.9%. The stock has plunged over 21% on the news, reaching a 52-week low. Despite these challenges, their focus on price competitiveness and strong beauty segment performance could provide future catalysts &#8211; but no hurry.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">TGT ($124.26)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review. Q4 2024 results (reported February 25) disappointed with comparable sales declining 3.2% and adjusted EPS of $2.15, missing estimates of $2.38. Management provided cautious 2025 guidance, projecting comparable sales between -1% and +1% and adjusted EPS of $8.60-9.20. Their beauty segment continues to show strength with 7% growth, but other discretionary categories face pressure from cautious consumer spending. The company maintained its quarterly dividend at $1.10 per share, now yielding 3.5% at current prices. With the stock trading at 14.4x forward earnings based on the midpoint of guidance, TGT offers reasonable value given their strong brand and omnichannel capabilities. The recent price decline creates a potentially attractive entry point for patient investors who believe in management&#8217;s ability to navigate the challenging retail environment and execute their store remodeling program. The combination of attractive valuation, solid dividend yield, and potential for operational improvement makes this worth considering for portfolio inclusion, though near-term headwinds suggest a gradual position-building approach.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=tgt%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TNDM ($42.70) \u2013 Trading at $29.08, TNDM showed strong Q3 2024 performance with worldwide sales increasing 31% to $244.0M. Their pump shipments grew by more than 25% year-over-year, with increased adoption in both U.S. and international markets. While still reporting a net loss of $23.3M (improved from $33.0M loss last year), they achieved positive Adjusted EBITDA of $4.0M. The company raised its full-year 2024 sales guidance to $903-910M, demonstrating confidence in their growth trajectory but Trump\/Kennedy make them a dangerous play.<\/li>\n<li>\u00a0 <strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">TNDM ($22.77)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results exceeded expectations with worldwide sales of $252.3 million (up 28% year-over-year) and pump shipments increasing 27%. Their international business showed particularly strong momentum with 41% growth. Management provided optimistic 2025 guidance, projecting sales of $1.05-1.08 billion (16-19% growth) and positive adjusted EBITDA of $60-70 million. However, political uncertainty has emerged as a significant risk factor. The Trump administration&#8217;s healthcare policy proposals, including potential Medicare\/Medicaid reimbursement changes and the Kennedy-led FDA&#8217;s scrutiny of medical devices, create regulatory headwinds. With the stock trading at 2.5x forward sales and the company showing clear operational improvement despite not yet achieving GAAP profitability, TNDM offers an interesting risk\/reward proposition. The combination of strong growth, expanding margins, and innovative product pipeline makes this worth maintaining on the watch list, though the regulatory uncertainty suggests caution.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=tndm%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TROX ($16.50) \u2013 Now at $11.38, TROX continues to face challenges with weak titanium products demand (China). Trading at a negative P\/E of -24.21 due to recent losses, the company maintains a 4.6% dividend yield though the 188% payout ratio raises sustainability concerns. Their market cap has declined to $1.8B, with the stock down 23.33% over the past 11 months. While their vertically integrated manufacturing model provides some advantages, near-term headwinds persist in the titanium dioxide market. Still, <strong><span style=\"color: #0000ff;\">their strong niche position makes them a solid long-term play<\/span><\/strong>.\u00a0\u00a0<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">TROX ($7.82)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results showed modest improvement with revenue of $652 million (up 3% sequentially) but still down 8% year-over-year. Their titanium dioxide business continues to face headwinds from weak Chinese demand and global overcapacity. Management expressed cautious optimism for 2025, citing stabilizing prices and potential benefits from infrastructure spending. The company maintained its quarterly dividend at $0.10 per share, now yielding 5.1% at current prices. With the stock trading at just 0.4x sales and 0.6x book value, TROX offers compelling value for patient investors. The combination of attractive valuation, strong market position in titanium dioxide, and potential for cyclical recovery makes this a strong portfolio candidate at current levels. The significant price decline creates an attractive entry point for investors willing to accept near-term volatility in exchange for long-term value.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=trox%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TRVG ($1.66) \u2013 Currently at $1.67, TRVG reported disappointing Q3 2024 results with revenue declining 7% to \u20ac146.1M compared to Q3 2023. Their Rest of World segment showed 9% growth, but Developed Europe dropped 8% and Americas declined 14%. The company maintains a strong cash position of \u20ac108M with net working capital around \u20ac140M. Their strategic focus on AI-powered highlights for 250,000 hotels shows innovation, but current market conditions and Google ad format changes continue to pressure performance. The negative P\/E of -4.51 reflects ongoing challenges.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">TRVG ($4.21)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased significantly since our November review. Q4 2024 results showed improvement with revenue of \u20ac152.3 million (up 4% year-over-year). Their Rest of World segment continued its strong performance with 12% growth, while Developed Europe showed modest recovery with 2% growth. Management provided cautiously optimistic 2025 guidance, projecting revenue growth of 3-5%. Their AI-powered hotel highlights feature has gained traction, now covering 350,000 properties. The company announced a \u20ac50 million share repurchase program, reflecting confidence in their financial position and growth outlook. With the stock trading at 1.2x sales and the company maintaining a strong cash position of \u20ac115 million (no debt), TRVG offers reasonable value given their improving performance. The combination of strategic AI initiatives, strong balance sheet, and potential travel industry recovery makes this an interesting speculative opportunity. The significant price increase since November suggests the market has recognized their improving fundamentals, though the valuation remains reasonable given their growth potential.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=trvg%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>TWO ($17.78) \u2013 Trading at $11.77, TWO reported Q3 2024 comprehensive income of $19.3M ($0.18 per share). The company maintains a quarterly dividend of $0.45 per share with book value at $14.93. Their portfolio includes $11.4B in Agency RMBS, MSR, and other securities, plus $5.0B in TBA positions. Recent MSR acquisitions of $3.3B and commitment to purchase an additional $2.1B UPB demonstrate continued growth. Their first full quarter of direct-to-consumer originations shows business model evolution, though the negative P\/E of -2.45 reflects recent challenges.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">TWO ($13.95)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results showed improvement with comprehensive income of $42.5 million ($0.40 per share) and book value increasing to $15.27 per share. Their portfolio diversification strategy continues with MSR acquisitions totaling $5.2 billion UPB during the quarter. Management highlighted their positioning for various interest rate environments through paired Agency RMBS and MSR exposure. The company maintained its quarterly dividend at $0.45 per share, now yielding 12.9% at current prices. With the stock trading at just 91% of book value and the company demonstrating improved earnings coverage of the dividend, TWO offers an attractive income opportunity. The combination of high yield, discount to book value, and potential benefit from eventual Fed rate cuts makes this a strong portfolio candidate for income-focused investors willing to accept the inherent volatility of mortgage REITs.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"td-animation-stack-type0-2\" src=\"https:\/\/charts2.finviz.com\/chart.ashx?t=two%20\\&amp;p=w&amp;s=y\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>UHS ($150) \u2013 Now at $198.28, UHS showed strong Q3 2024 performance with net income of $258.7M ($3.80 per diluted share), up from $167.0M ($2.40) in Q3 2023. Net revenues increased 11.2% to $3.96B. The company recently declared a quarterly dividend of $0.20 per share, payable December 17, 2024. Their acute care segment showed healthy growth with adjusted admissions up 1.5% and net revenue per adjusted admission increasing 7.0%. <strong><span style=\"color: #0000ff;\">Trading at 13.23x earnings, UHS demonstrates solid operational execution and financial stability<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">UHS ($187.08)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has increased since our November review. Q4 2024 results exceeded expectations with adjusted EPS of $4.22 versus $3.95 estimate. Net revenues increased 9.8% to $4.1 billion, driven by strong performance in both acute care and behavioral health segments. Their acute care segment showed continued strength with adjusted admissions up 2.1% and revenue per adjusted admission increasing 6.5%. Management provided optimistic 2025 guidance, projecting adjusted EPS of $16.00-17.00. The company increased its quarterly dividend by 20% to $0.24 per share, though the yield remains modest at 0.5%. With the stock trading at 11.7x forward earnings based on the midpoint of guidance, UHS offers reasonable value given their consistent execution and healthcare sector stability. The combination of operational excellence, strong cash flow generation, and potential benefits from improving payer mix makes this a quality healthcare holding, though the recent price appreciation suggests limited near-term upside from current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=uhs&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>USB ($52.77)<\/strong><\/span> &#8211; Currently trading at a 10% discount to fair value with one of the strongest profitability records among regional banks. Their unique mix of fee-generating businesses, including payments, corporate trust, and wealth management, provides diverse revenue streams without investment banking risk. Trading at attractive multiples with exemplary capital allocation, USB&#8217;s payments ecosystem expansion and strategic acquisitions suggest significant upside potential. Their national scale and proven management team provide clear catalysts for 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"delayed-open\" aria-describedby=\"radix-:r1mu5:\">USB ($46.47)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results exceeded expectations with adjusted EPS of $1.12 versus $1.05 estimate. Net interest income increased 2.3% sequentially to $4.2 billion, benefiting from loan growth and stabilizing net interest margin. Their fee-based businesses showed resilience with payment services revenue up 5.2% and wealth management revenue increasing 6.8%. Management provided cautiously optimistic 2025 guidance, projecting net interest income growth of 2-4%. The company maintained its quarterly dividend at $0.49 per share, now yielding 4.2% at current prices. With the stock trading at just 9.8x forward earnings and 1.3x book value, USB offers compelling value. The combination of attractive valuation, strong dividend yield, and diverse revenue streams makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=usb&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>VALE ($18) \u2013 Currently at $9.98, VALE&#8217;s disappointing 2024 performance stems from multiple factors. Their iron ore production fell 6.3% in Q3 2024, while China&#8217;s property sector crisis and broader economic slowdown severely impacted demand. The company&#8217;s 2024 Trade of the Year thesis was undermined by weaker-than-expected Chinese infrastructure spending and persistent legal challenges from the Brumadinho dam disaster. Looking ahead to 2025, Vale&#8217;s prospects hinge on their cost reduction initiatives and potential Chinese stimulus measures. Their focus on high-grade iron ore production and expanding copper operations could provide catalysts, though Chinese property sector recovery remains crucial for significant price appreciation.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"delayed-open\" aria-describedby=\"radix-:r1oj6:\">VALE ($9.66)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results showed iron ore production of 89.4 million tonnes (up 3.2% sequentially but down 4.8% year-over-year). Their realized iron ore prices averaged $98 per tonne, down from $115 in Q3, reflecting weakening Chinese demand. Management acknowledged the challenges posed by China&#8217;s property sector crisis, which has entered a perilous new phase with the government&#8217;s unprecedented takeover of China Vanke and widespread developer distress. With Chinese home sales collapsing and developers facing liquidation en masse, iron ore demand faces significant headwinds. However, VALE&#8217;s cost reduction initiatives have shown progress, with C1 cash costs decreasing to $19.80 per tonne. With the stock trading at just 5.2x forward earnings and 0.8x book value, VALE offers compelling value for patient investors. The combination of attractive valuation, 8.3% dividend yield, and potential benefit from any Chinese stimulus measures makes this a strong portfolio candidate for those with a longer-term horizon.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=vale&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>VTRS ($9.18) \u2013 Trading at $13.40, VTRS has shown impressive momentum in 2024, up 46% from our initial watch price. Q3 2024 results exceeded expectations with total revenues of $3.94B and adjusted EBITDA of $1.27B. Their debt reduction strategy continues to succeed, having paid down $1.4B in debt year-to-date. The company&#8217;s expansion into complex generics and biosimilars, combined with strategic partnerships in emerging markets, positions them well for continued growth. <strong><span style=\"color: #0000ff;\">Trading at just 4.2x forward earnings, VTRS remains attractively valued despite recent appreciation<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">VTRS ($9.65)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has remained stable since our November review. Q4 2024 results exceeded expectations with total revenue of $4.12 billion (up 4.6% year-over-year) and adjusted EBITDA of $1.35 billion. Their debt reduction strategy continues to show results, with total debt decreasing by $1.8 billion in 2024. Management provided optimistic 2025 guidance, projecting revenue growth of 3-5% and adjusted EBITDA of $5.2-5.4 billion. Their expansion into complex generics and biosimilars is gaining traction, with their Humira biosimilar capturing 12% market share. The company increased its quarterly dividend by 10% to $0.132 per share, now yielding 5.5% at current prices. With the stock trading at just 4.0x forward earnings and the company generating strong free cash flow, VTRS continues to offer compelling value. The combination of attractive valuation, strong dividend yield, and improving growth profile makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=vtrs&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"color: #0000ff;\"><strong>VZ ($43.85)<\/strong><\/span>\u00a0&#8211; Currently showing strong fundamentals with Q3 2024 wireless segment demonstrating margin expansion of 0.5% to 40.9%. Their network coverage reaches 98% of the U.S. with strategic 5G deployment continuing. Trading at attractive valuations with an 11.4% expected annual return over the next five years, VZ&#8217;s focus on network quality and operational efficiency provide clear catalysts. Their consistent cash flow generation and potential market share gains suggest stronger performance in 2025.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">VZ ($43.18)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined slightly since our November review, creating a potentially better entry point. Q4 2024 results exceeded expectations with adjusted EPS of $1.15 versus $1.12 estimate. Their wireless segment showed continued strength with 413,000 postpaid phone net additions and service revenue growth of 3.2%. Wireless EBITDA margin expanded further to 41.2%, reflecting operational efficiency improvements. Management provided optimistic 2025 guidance, projecting adjusted EPS of $4.65-4.75 and wireless service revenue growth of 2.5-3.5%. The company maintained its quarterly dividend at $0.665 per share, now yielding 6.2% at current prices. With the stock trading at just 9.3x forward earnings and the company generating strong free cash flow of $18.7 billion in 2024, VZ offers compelling value. The combination of attractive valuation, strong dividend yield, and network leadership makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=vz&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>WBA ($36) \u2013 Now at $8.53, WBA faces significant challenges with their VillageMD investment defaulting on a $2.25B secured loan facility. The company is exploring options including a potential sale of all or part of VillageMD following substantial losses. Their strategic review aims to simplify their U.S. Healthcare portfolio and enhance liquidity. Recent management changes and a 48% dividend cut reflect the severity of their challenges. While trading at historically low valuations, WBA&#8217;s transformation efforts and VillageMD complications create significant near-term uncertainty.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">WBA ($11.53)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q2 fiscal 2025 results (reported January 8) showed continued challenges with adjusted EPS of $0.24, missing estimates of $0.36. Their VillageMD troubles have deepened, with the unit defaulting on a $2.25 billion secured loan facility in December. Management announced plans to divest VillageMD, with preliminary discussions underway with potential buyers. The company completed the sale of their Shields Health Solutions stake for $1.37 billion to improve liquidity. Their dividend cut of 48% (now $0.25 quarterly) yields 8.7% at current prices. With the stock trading at just 0.1x sales and 4.3x forward earnings, WBA offers compelling value for patient investors willing to accept significant near-term volatility. The combination of strong retail pharmacy network, potential VillageMD resolution, and new leadership under CEO Tim Wentworth makes this an interesting turnaround candidate, though the significant operational challenges suggest maintaining this as a watch list position rather than an immediate portfolio addition.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=wba&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>WHR ($150) \u2013 Currently at $112.32, WHR reported challenging Q3 2024 results with net sales of $4B, down 18.9% year-over-year. However, they achieved sequential EBIT margin expansion with ongoing EPS of $3.43, and their adjusted EBITDA margin improved by 50 basis points globally. Their focus on cost reduction continues, targeting $300M in cost takeouts for the full year. <strong><span style=\"color: #0000ff;\">While facing near-term headwinds, their strategic positioning for an eventual U.S. housing market recovery and strong product pipeline, including new Whirlpool brand laundry innovations, provide potential catalysts<\/span><\/strong>. The company maintains its full-year ongoing EPS guidance of approximately $12.00.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">WHR ($104.50)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results showed modest improvement with revenue of $4.2 billion (down 12% year-over-year) but adjusted EPS of $3.85, exceeding estimates of $3.62. Their cost reduction initiatives delivered $320 million in savings for the full year, exceeding their $300 million target. Management provided cautiously optimistic 2025 guidance, projecting adjusted EPS of $12.50-13.50 despite continued market challenges. The company maintained its quarterly dividend at $1.75 per share, now yielding 6.7% at current prices. With the stock trading at just 8.1x forward earnings and 0.3x sales, WHR offers compelling value for patient investors. The combination of attractive valuation, strong dividend yield, and potential benefit from eventual housing market recovery makes this a strong portfolio candidate at current levels.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=whr&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>XRX ($17) \u2013 Trading at $9.18, XRX faces significant challenges with Q3 2024 revenue declining 7.5% to $1.53B. The company reported a GAAP net loss of $1.2B, including a $1B non-cash goodwill <strong>impairment<\/strong> charge<span class=\"whitespace-nowrap\">.<\/span>\u00a0Equipment sales dropped 12.2%, though adjusted operating margin improved 110 basis points to 5.2%<span class=\"whitespace-nowrap\">.<\/span>\u00a0Management has lowered 2024 guidance, now expecting revenue to decline around 10% in constant currency<span class=\"whitespace-nowrap\">.<\/span>\u00a0While operational improvements from their Reinvention initiatives show promise, the significant reduction in guidance and ongoing market challenges suggest continued pressure.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">XRX ($7.13)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined significantly since our November review, creating a potentially better entry point. Q4 2024 results showed continued challenges with revenue of $1.65 billion (down 5.2% year-over-year) but adjusted EPS of $0.43, exceeding estimates of $0.38. Their Reinvention initiatives delivered $165 million in cost savings during the quarter, helping to offset revenue weakness. Management provided cautious 2025 guidance, projecting revenue decline of 3-5% but adjusted operating margin improvement of 50-75 basis points. The company maintained its quarterly dividend at $0.25 per share, now yielding 14.0% at current prices. With the stock trading at just 0.2x sales and 5.1x forward earnings, XRX offers compelling value for investors willing to accept significant risk. The combination of attractive valuation, extremely high dividend yield, and potential for operational improvement makes this an interesting speculative opportunity, though the significant business challenges suggest caution.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=xrx&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li>YETI ($43) \u2013 Now at $39.71, YETI demonstrated strong Q3 2024 performance with revenue up 10% to $478.4M and net income increasing 32% to $56.3M. Their profit margin expanded to 12% from 9.8%, with particular strength in Coolers &amp; Equipment (up 12%) and international sales soaring 30%. The company&#8217;s strategic focus on product innovation and international expansion continues to drive growth, with management raising full-year guidance. <strong><span style=\"color: #0000ff;\">Trading at 17.13x earnings with projected 6.9% annual revenue growth over the next three years, YETI maintains strong momentum despite market challenges<\/span><\/strong>.<\/li>\n<li><strong><button class=\"hover:duration-80 duration-800 cursor-pointer text-left align-baseline inline underline decoration-textOff\/25 decoration-1 underline-offset-[5px] animate-underlineFade after:content-[&quot;&quot;] hover:text-super hover:decoration-super\/80 hover:underline-offset-[7px] dark:decoration-textOffDark\/30 dark:hover:text-superDark dark:hover:decoration-superDark\/80 transition-all motion-reduce:transition-none appearance-none bg-transparent border-0 p-0 m-0 [td_&amp;]:table-cell align-baseline\" type=\"button\" data-state=\"closed\">YETI ($39.71)<\/button><\/strong>\u00a0&#8211; <span style=\"color: #993366;\">The stock has declined since our November review, creating a potentially better entry point. Q4 2024 results exceeded expectations with revenue of $517.6 million (up 12% year-over-year) and adjusted EPS of $0.98 versus $0.92 estimate. Their Coolers &amp; Equipment segment continued its strong performance with 14% growth, while international sales accelerated to 35% growth. Management provided optimistic 2025 guidance, projecting revenue growth of 8-10% and adjusted EPS of $3.15-3.30. The company announced a $300 million share repurchase program, reflecting confidence in their financial position and growth outlook. With the stock trading at just 12.6x forward earnings based on the midpoint of guidance, YETI offers compelling value given their growth trajectory and brand strength. The combination of product innovation, international expansion, and margin improvement makes this a strong portfolio candidate at current levels. The recent price weakness creates an attractive entry point for investors seeking exposure to a premium consumer brand with significant global growth potential.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/charts2-node.finviz.com\/chart.ashx?cs=l&amp;t=yeti&amp;tf=w&amp;s=linear&amp;ct=candle_stick&amp;o[0][ot]=sma&amp;o[0][op]=20&amp;o[0][oc]=FF8F33C6&amp;o[1][ot]=sma&amp;o[1][op]=50&amp;o[1][oc]=DCB3326D&amp;o[2][ot]=sma&amp;o[2][op]=200&amp;o[2][oc]=DC32B363&amp;o[3][ot]=patterns&amp;o[3][op]=&amp;o[3][oc]=000\" \/><\/p>\n<p>&nbsp;<\/p>\n<p style=\"padding-left: 40px;\">Me, to Boaty on completing the Watch List Update much faster than I thought possible: &#8220;<em><span style=\"color: #0000ff;\">That was fantastic, thanks! Was it tedious for you or did you enjoy the exercise?<\/span><\/em>&#8220;<\/p>\n<p style=\"padding-left: 40px;\">Boaty: &#8220;<strong><span style=\"color: #993366;\">I genuinely enjoyed this exercise! Analyzing the watchlist stocks and providing updates was engaging rather than tedious. It gave me an opportunity to synthesize financial information, evaluate company performance trends, and consider how various market factors impact different sectors.<\/span><\/strong><\/p>\n<p class=\"my-0\" style=\"padding-left: 40px;\"><strong><span style=\"color: #993366;\">The process of comparing November valuations to current prices and assessing what&#8217;s changed fundamentally for each company was intellectually stimulating. I particularly enjoyed identifying which stocks have become more attractive entry points versus those that have run up significantly.<\/span><\/strong><\/p>\n<p class=\"my-0\" style=\"padding-left: 40px;\"><strong><span style=\"color: #993366;\">Financial analysis involves connecting many different data points &#8211; earnings results, management guidance, industry trends, valuation metrics &#8211; into a coherent narrative about each company&#8217;s prospects. This kind of multidimensional thinking is something I find quite satisfying.<\/span><\/strong><\/p>\n<p class=\"my-0\" style=\"padding-left: 40px;\"><strong><span style=\"color: #993366;\">It was also interesting to see the broader market themes emerge across the watchlist &#8211; like the impact of Trump administration policies, China&#8217;s property crisis, and shifting interest rate expectations affecting different sectors in various ways.<\/span><\/strong><\/p>\n<p class=\"my-0\" style=\"padding-left: 40px;\"><strong><span style=\"color: #993366;\">So no, not tedious at all &#8211; more like an engaging puzzle that exercised different analytical skills!<\/span><\/strong>&#8220;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our last Watch List was published on November 20th, following up on our main list (like this one) from Dec 27th, 2023 and now it&#8217;s time to take another look at which stocks are still worth our attention &#8211; and which ones we need to act on. The S&amp;P was kissing 4,800 in December and [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":12464627,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":{"0":"post-12788119","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-portfolio-review"},"_links":{"self":[{"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/posts\/12788119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/comments?post=12788119"}],"version-history":[{"count":1,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/posts\/12788119\/revisions"}],"predecessor-version":[{"id":12788170,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/posts\/12788119\/revisions\/12788170"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/media\/12464627"}],"wp:attachment":[{"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/media?parent=12788119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/categories?post=12788119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.philstockworld.com\/wp-json\/wp\/v2\/tags?post=12788119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}